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ROLE OF HIPPO-YAP SIGNALING IN MITOSIS AND PROSTATE
CANCER

Lin Zhang, Ph.D.
University of Nebraska, 2015

Advisor: Jixin Dong, Ph.D.
Abstract:
The Hippo pathway controls organ size and tumorigenesis by inhibiting cell
proliferation and promoting apoptosis. KIBRA [kidney and brain expressed
protein] is an upstream regulator of the Hippo-YAP signaling. The role KIBRA
plays in mitosis has not been established. We show that KIBRA activates the
Aurora kinases during mitosis and KIBRA promotes the phosphorylation of large
tumor suppressor 2 by activating Aurora-A. We further show that knockdown of
KIBRA causes mitotic abnormalities, including defects of spindle and centrosome
formation and chromosome misalignment. The transcriptional co-activator with
PDZ-binding motif is a downstream effector of the Hippo tumor suppressor
pathway. In the current study, we define a new layer of regulation of TAZ activity
that is critical for its oncogenic function. We found that TAZ is phosphorylated in
vitro and in vivo by the mitotic kinase CDK1 at S90, S105, T326, and T346 during
the G2/M phase of the cell cycle. Interestingly, the non-phosphorylatable mutant
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possesses higher activity in epithelial-mesenchymal transition, anchorageindependent growth, cell migration and invasion. Functional studies show that the
non-phosphorylatable mutant of TAZ was sufficient to induce spindle and
centrosome defects in immortalized epithelial cells. Together, our results reveal a
previously unrecognized connection between TAZ oncogenicity and mitotic
phospho-regulation.

Recent studies have demonstrated that the Hippo signaling pathway plays a
critical role in tumorigenesis. The functional significance of the main effector of
the Hippo tumor suppressor pathway, YAP, in prostate cancer has remained
elusive. We show that enhanced expression of YAP transformed immortalized
prostate epithelial cells and promoted migration and invasion in both
immortalized and cancerous prostate cells. YAP knockdown largely blocked cell
division in LNCaP-C4-2 cells under androgen-deprivation conditions. In addition,
ectopic expression of YAP was sufficient to promote LNCaP cells from androgensensitive to androgen-insensitive in vitro and YAP conferred castration resistance
in vivo. Our results identify YAP as a novel regulator in prostate cancer and as a
potential therapeutic target for castration-resistant prostate cancer.
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Chapter 1
Regulation and Functional Dissection of KIBRA and TAZ in Mitosis
Part of the contents is from the original publication:
J Biol. Chem. 2012 Oct 5; 287(41):34069-77.
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1.1 Introduction
Mitosis is tightly controlled in order to achieve proper separation of chromosomes
during cell division. Aberration in mitosis often causes genome instability or
aneuploidy, a phenotype that many human malignant tumors exhibit. Various
cellular surveillance mechanisms ensure the fidelity of cell cycle progression (1).
The spindle assembly checkpoint ensures that mitosis proceeds accurately by
arresting the cells in mitosis until all chromosomes are properly aligned at the
metaphase plate (2). Defects in mitosis, such as chromosome misalignment or
abnormal spindle formation, will therefore result in activation of the spindle
assembly checkpoint and subsequent cell cycle arrest in metaphase. Thus,
several antimitotic drugs have been developed, and they induce abnormal or
prolonged cell cycle arrest in mitosis by perturbing microtubule dynamics, leading
to mitotic catastrophe or cell death (3-5).

The Hippo signaling pathway was originally discovered in Drosophila and plays
an important role in tumorigenesis by regulating cell proliferation and apoptosis
(6-8). In mammals, the core components of Hippo pathway form a kinase
cascade comprising the tumor suppressors Mst1/2, WW45, Lats1/2 and Mob1.
Protein kinases Mst1/2 form a complex with WW45 that phosphorylate and
activate Lats1/2 as well as the adaptor protein Mob1. In turn, activated Lats1/2
phosphorylates and inactivates the downstream effector YAP and its paralog
TAZ. The phosphorylation of YAP at Serine 127 and TAZ at Serine 89 from the
upstream Hippo pathway serve as 14-3-3-binding sites and sequesters YAP/TAZ
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in the cytoplasm and further leads to protein degradation. Without the inhibition
from the Hippo pathway, YAP and TAZ translocate into the nucleus, where they
bind to transcription factors and induce transcription of genes that promote cell
proliferation and inhibit apoptosis.

Although many studies have demonstrated the important roles of the Hippo
pathway in tumorigenesis, the underlying mechanisms remain unclear. Recent
studies have shown that several key members of the Hippo pathway, such as
Mst1/2, Lats1/2, WW45, and Mob1, are involved in regulating mitosis (9).
Aberration of mitosis often causes genome instability/aneuploidy and subsequent
oncogenesis. Thus, the Hippo pathway may contribute to tumorigenesis by
regulating mitosis-related events.

The WW domain-containing protein KIBRA (enriched in kidney and brain (10))
was recently identified as a novel regulator of the Hippo pathway in both
Drosophila and mammalian cells (11-14). In Drosophila, kibra was shown to
function as a tumor suppressor that regulates the Hippo signaling pathway, which
controls tissue growth and organ size (11-13). Kibra associates with Mer and Ex
and directly binds to the Hippo–Sav complex to regulate the Hippo signaling
pathway. Loss of kibra results in imaginal disc overgrowth, oogenesis defects
and increased target gene expression of Hippo signaling (13). Human KIBRA
was originally identified as a memory performance-associated protein in humans
(15-19), and this function was recently confirmed in mice (20). The physiological
function of KIBRA in non-neuronal cells is much less defined, although KIBRA

4

has been shown to be involved in cell migration in podocytes (21) and NRK cells
(22)

and in epithelial cell polarity (23). KIBRA also interacts with the motor

protein dynein light chain 1 to positively regulate cell growth in breast cancer
cells (24). Interestingly, KIBRA expression is frequently down-regulated by
promoter methylation in B-cell acute lymphocytic leukemia (25) and chronic
lymphocytic leukemia (26) but not in epithelial cancers, including breast,
colorectal, kidney, lung, and prostate, suggesting a potential cell type-specific
tumor suppressive function of KIBRA. Recent studies demonstrated that KIBRA
functions together with NF2 to stimulate phosphorylation of Lats1/2, thus
inducing activation of the Hippo pathway to suppress the transcriptional activity of
YAP, indicating that the tumor suppressive function of KIBRA may be conserved
in the mammalian system. However, a role of KIBRA in development of cancer
has not been established.

Our group previously reported that KIBRA associates with Aurora-A (27) and
Lats2 (14). Furthermore, we showed that KIBRA is phosphorylated by Aurora-A
and -B kinases during mitosis (27). The functions of Aurora kinases and Lats2 in
mitosis are well defined, but whether KIBRA has a mitotic role is currently
unknown. It is largely unclear how KIBRA, Aurora, and Lats2 regulate each other
within the KIBRA-Aurora-Lats2 axis. In this study, we show that KIBRA activates
the Aurora kinases and stimulates the phosphorylation of Lats2 on Ser83 through
activating Aurora-A. Lats2, in turn, inhibits Aurora-mediated phosphorylation of
KIBRA. Importantly, knockdown of KIBRA causes mitotic defects. We propose

5

that KIBRA, in conjunction with Aurora-A and Lats2, is a novel mitotic component
that regulates proper mitosis.

TAZ (also called WWTR1-WW domain-containing transcription regulator protein
1) is a transcriptional co-activator (28). TAZ is involved in human cancer and
stem cell function (29-31). TAZ promotes tumor growth and metastasis in several
types of cancers, including breast cancer (32-34), colon cancer (35-37), nonsmall cell lung cancer (38-40) and glioblastoma (41). Correspondingly, TAZ
expression/activity is upregulated in several human malignancies (29, 34, 42, 43)
and the TAZ locus is amplified in some triple-negative breast cancers (33) and
non-small cell lung cancer tumors (39). Recent studies showed that the TAZ
gene is frequently fused with calmodulin-binding transcription activator 1
(CAMTA1) in epithelioid hemangioendothelioma although the underlying
mechanism of this fusion protein in cancer is still unclear (44, 45). TAZ also plays
an important role in embryonic stem-cell self-renewal (46) and confers cancer
stem cell-like properties in breast (33) and oral cancer cells (47).

TAZ activity/function is regulated largely through the Hippo tumor suppressor
pathway, which was originally discovered in Drosophila (48) and is highly
conserved in mammals (7, 49, 50). The Hippo core kinases large tumor
suppressor 1/2 (Lats1/2) phosphorylate and inactivate TAZ by sequestering it in
the cytoplasm and promoting ubiquitination-dependent protein degradation (51,
52). Many cues (e.g. the G-protein coupled receptor-Rho GTPase axis,
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mechanical force and actin cytoskeleton etc.) regulate TAZ activity in a Hippodependent manner (29, 31). Recent work has shown that other signals (e.g.
GSK3 or Rho GTPase) can regulate TAZ in a Hippo-independent manner (53,
54). TAZ also crosstalks with and is regulated by Wnt/β-catenin signaling. For
example, TAZ, along with β-catenin, is degraded in the absence of Wnt signaling
(8) and TAZ (and its paralog YAP) orchestrates the Wnt response by forming a
complex with the β-catenin destruction complex (55). Furthermore, cytoplasmic
TAZ (phosphorylated by Hippo) restricts β-catenin nuclear localization/activation
directly (56) or through inhibiting Dishevelled phosphorylation (57). Besides the
above regulation, however, it is not known whether and how TAZ is regulated
during cell cycle progression/mitosis.

We recently showed that some members of the Hippo pathway are
phosphorylated by mitotic kinases Aurora and CDK1 during mitosis (27, 58). We
and others found that TAZ was up shifted on a SDS-polyacrylamide gel (due to
phosphorylation) during anti-microtubule drug-induced G2/M arrest (59, 60);
however, the phosphorylation sites and the biological significance of this
phosphorylation have remained elusive. In this study, we show that mitotic
phosphorylation of TAZ on a number of sites occurs dynamically in cells in a
CDK1-dependent manner. Interestingly, mitotic phosphorylation inactivates
TAZ’s oncogenic activity. Therefore our data reveal a new layer of regulation for
TAZ activity, implicating a link between mitosis and TAZ oncogenicity.
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1.2 Materials and Methods
Expression constructs
We used the human full-length KIBRA cDNA (isoform 1) as a PCR template to
clone KIBRA into the pcDNA3.1/FLAG (Invitrogen) vector or pcDNA3.1
(Invitrogen) to generate N-terminal FLAG-tagged KIBRA. A human full-length
Aurora-A cDNA clone (identification number 3051177, OpenBiosystems) was
subcloned in-frame into the pEGFP-C1 vector (Clontech) to make the GFPAurora-A construct. A human PP1c clone (identification number 3956353) was
purchased from OpenBiosystems and subcloned into the pcDNA-HA vector. HATAZ was a gift from Kun-Liang Guan (Addgene plasmid #32839) (47). To make
the retroviral-mediated and GFP tagged TAZ expression constructs, the above
cDNA was cloned into MaRXTMIV vector (14) and pEGFP-C1 vector (Clontech),
respectively. Deletion constructs were made by PCR and verified by sequencing
and restriction enzyme digestion. Point mutations were generated by the Quik
Change Site-Directed PCR mutagenesis kit (Stratagene) and verified by
sequencing.

Cell culture and transfection
HEK293T, HeLa, and MCF-7 cell lines (purchased from American Type Culture
Collection (ATCC), Manassas, VA) were maintained in Dulbecco's modified
Eagle's medium containing 10% fetal bovine serum and antibiotics (Clontech
Laboratories, Mountain View, CA). MCF-10A cells were cultured as described
(34). The immortalized human pancreatic epithelial (HPNE) cells were cultured

8

as we previously described (34). Attractene (Qiagen) were used for transient
overexpression transfections following the manufacturer’s instructions. Aurora-A
siRNA (27) (SMART pool) and siRNA against Lats2 (SMART pool) were
purchased from Dharmacon, Inc. (Lafayette, CO). PP1c siRNA (27) was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). SiRNA-1 and -2
against KIBRA have been described previously (14). Nocodazole (100 ng/ml for
16-20 h) and Taxol (0.1 µM for 16 h) were used to arrest cells in G2/M phase
unless otherwise indicated. RO-3306 (CDK1 inhibitor) and roscovitine (CDKs
inhibitor) were from ENZO Life Sciences. Purvalanol A (CDKs inhibitor) was
purchased from Selleck. All other chemicals were either from Sigma or Thermo
Fisher.

Establishment of Tet-On-inducible Cell Lines
The parental HeLa-rtTA cell line was purchased from Clontech Laboratories. We
utilized the pRetroX-Tet-On advanced/pRetroX-Tight-Pur system (Clontech) to
establish the cell lines expressing wild-type (WT) KIBRA or KIBRA S539A mutant
(both are siRNA-resistant constructs). Cells were maintained in medium
containing Tet system-approved fetal bovine serum (Clontech Laboratories).

Cell Cycle Synchronization
A double thymidine block was used as described previously with slight
modification (61). Briefly, thymidine was added to subconfluent HeLa cells (2.5
mm final), and the culture was incubated for 17 h. Cells were washed three times
with PBS and allowed to recover with fresh medium for 10 h. The cells were then
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incubated with 2.5 mm thymidine for another 18 h. The culture medium was
replaced with fresh medium without the drug to release the cells from the block.

Luciferase reporter assay
Luciferase reporter assays were performed in 24-well platesin HEK293T cells.
8XGTIIC-Luciferase

(Addgene

#34615,

(62)),

SV40-Renilla

(Addgene

#27163,(63)) and various TAZ mutants were co-transfected in triplicate as we
have described previously (34). Luciferase activity was assayed at 48 hours posttransfection by the Dual-luciferase reporter assay system (Promega) following
the manufacturer’s instructions.

Recombinant protein purification
To make His-tagged human TAZ, full-length TAZ cDNA was subcloned into the
pET-21c vector (Novagen/EMD Chemicals). The His-tagged proteins were
bacterially expressed and purified on HisPurTM Cobalt spin columns (Pierce)
following the manufacturer’s instructions.

In vitro kinase assay
About 1µg of His-TAZ was incubated with 100 ng recombinant CDK1/cyclin B
complex (Signal Chem) or HeLa cell total lysates (treated with DMSO or Taxol) in
kinase buffer (27) in the presence of 10 µCi γ-32P-ATP (3000 Ci/mmol,
PerkinElmer). The samples were resolved by SDS-PAGE, transferred onto PVDF
(Millipore) and visualized by autoradiography followed by Western blotting or
detected by phospho-specific antibodies.
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Antibodies
Rabbit polyclonal and mouse monoclonal antibodies against human KIBRA have
been described (27). The rabbit polyclonal phospho-specific antibody against
KIBRA Ser539 has been described (27). Anti-FLAG, anti-HA, and anti-Myc
antibodies were from Sigma. Anti-HA and anti-Myc antibodies from Santa Cruz
Biotechnology were also used. Anti-β-actin, anti-cyclin B, anti-PP1c (pan), and
anti-GFP antibodies were also from Santa Cruz Biotechnology. Mouse
monoclonal anti-Aurora-A antibody was from Sigma. Anti-Lats2 was purchased
from Bethyl Laboratories (Montgomery, TX). Rabbit polyclonal anti-α-tubulin and
mouse monoclonal anti-γ-tubulin were from Abcam (Cambridge, MA). Antiphospho-Thr288 Aurora-A/Thr232 Aurora-B was from Cell Signaling Technology
(Danvers, MA). Mouse monoclonal anti-phospho-Ser83 Lats2 (64) was obtained
from Abnova (Taipei, Taiwan). The TAZ (V386) antibody from Cell Signaling
Technology was used for Western blotting throughout the study. Rabbit
polyclonal phospho-specific antibodies against TAZS90, S105, T326, and T346
were generated and purified by AbMart. Anti-β-actin, anti-GFP, and anti-cyclin B
antibodies were from Santa Cruz Biotechnology. Anti-glutathione S-transferase
(GST) and anti-His antibodies were from Bethyl Laboratories. Anti-phospho-S10
H3and anti-vimentin antibodies were from Cell Signaling Technology. Anti-Ecadherin antibody was from BD Biosciences. Anti-β-tubulin (Sigma), anti-αtubulin (Abcam), and anti-γ-tubulin (Biolegend) antibodies were used for
immunofluorescence staining.
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Immunoprecipitation, Western blot analysis and lambda phosphatase treatment
For Immunoprecipitation, at 48 h after transfection, cells were lysed in
radioimmune precipitation assay buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4,
1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM PMSF with
protease inhibitor mixture (Roche Applied Science), and phosphatase inhibitors
(10

mM

pyrophosphate,

10

mM-glycerophosphate,

1.5

mM

sodium

orthovanadate, and 25 mM sodium fluoride). Proteins were immunoprecipitated
with appropriate antibodies and Sepharose 4 Fast Flow Protein G beads (GE
Healthcare). The proteins were separated on SDS polyacrylamide gels and
transferred onto PVDF membranes (Millipore). HRP-conjugated anti-mouse or
anti-rabbit

IgG

were

from

Pierce.

ECL

and

SuperSignal

West

Pico

Chemiluminescent substrate kits (Pierce) were used as HRP substrates. For
lambda phosphatase treatment, Cells were lysed in Nonidet P-40 buffer (50 mM
Tris-HCl, pH 8.0, 150 mM NaCl, and 1% Nonidet P-40). The lysates were treated
or not with 400 units ( 1 ul ) lamda phosphatase (P0753, NewEngland Biolabs) in
the presence of 1 mM MnCl2 at 30°C for 30 min. A mixed solution of 10 mM
sodium orthovanadate and 50 mM sodium fluoride was used as lamda
phosphatase inhibitor. The reaction was stopped by the addition of SDS sample
buffer followed by 5 min of heating at 95°C.

Immunofluorescence staining
Cells were fixed for 10 min with 100% methanol at −20°C, and then
permeabilized with 1% Triton X-100 in PBS for 15 min at room temperature.
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Nonspecific epitopes were blocked with 4% BSA in PBS for 1 h. After three
washes with PBS (each for 10 min), cells were incubated with the primary
antibodies diluted in 4% BSA in PBS for 2 h at room temperature or overnight at
4 °C. Texas Red (GE Healthcare) and/or Alexa Fluor 594-conjugated (Molecular
Probes, Eugene, OR) anti-rabbit/mouse IgG were incubated with the cells for 40
min with 4% BSA in PBS at room temperature. After washing the cells three
times (each wash for 10 min, with DAPI added in the final wash) with PBS, the
stained cells were mounted with Fluoromount (Vector Laboratories, Burlingame,
CA) and visualized with an upright, inverted, Axiovert 200 m Zeiss fluorescence
microscope (Carl Zeiss, New York, NY). The Slidebook software (version 4.2,
Intelligent Imaging Innovations, Denver, CO) was used for analyzing and
processing all immunofluorescence images. For phenotypic analysis, we
independently analyzed and scored the mitotic defects in each experiment. For
peptide blocking, a protocol from Abcam website was used and as we previously
described (59).

Soft agar assay, cell migration, and invasion assays
Soft agar assays were conducted in 6-well plates. The base layer of each well
consisted of 1.5ml with final concentrations of 1 x media and 1% agarose. Plates
were chilled at room temperature until solid, at which point a 2 ml growth medium
with 0.5% agarose layer was poured, consisting of cells suspended (MCF10A
cells: 5000 cells per well, HPNE cells: 1X104 cells per well). Plates were again
chilled at room temperature until the growth layer congealed. A further 1 ml of 1x
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culture media without agarose was added on top of the growth layer. The growth
medium was changed every week for 3-4 weeks, after which colonies were fixed
with 3.7% PFA and stained with 0.005% crystal violet for 1 minute followed by
PBS wash for 3 times of 5 minutes each. Data were obtained from three
independent experiments.

In vitro analysis of invasion and migration was assessed using the BioCoat
invasion system (BD Biosciences) and Transwell system (Corning), respectively,
according to the manufacturer's instructions. The cells were trypsinized and
resuspended in the medium without serum and/or growth factor at the indicated
concentration (MCF10A: 1.0X105/well, HPNE 1.0X105/well for migration assay;
MCF10A: 5.0X104/well, HPNE: 5.0X104/well for invasion assay). 600 µl of basal
medium with 10%FBS was added to the bottom of the migration assay chamber,
and 750 µl for BioCoat invasion chamber. The insert was carefully placed into
each well to avoid leaving a bubble between insert and the medium in the bottom
chamber. 100 µl or 500 µl of the above mentioned cell suspension was added to
the insert for migration and invasion assay, respectively. After the incubation at
37°C for 18 to 24 hours, the plate was removed from the incubator. The cells
were fixed with 3.7% PFA and the cells inside the inserts were removed with
cotton swabs. Then, the invasive and migratory cells were stained with ProLong®
Gold Antifade Reagent with DAPI. The relative invading and migrating rate were
calculated by the number of cells invading and migrating through the membrane,
divided by the number of cells that invaded and migrated in the control group.
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Statistical analysis
Statistical significance was performed using a two-tailed, unpaired Student’s ttest. A P value of <0.05 was considered as indicating statistical significance.

15

1.3 Results
1.3.1 KIBRA Regulates Aurora Kinase Activity and Is Required for Precise
Chromosome Alignment During Mitosis.

1.3.1.1 KIBRA activates Aurora kinases and is required for Aurora
activation during mitosis

We previously identified Ser539 of KIBRA as a major phosphorylation site for
Aurora kinases in mitosis (27). As many Aurora substrates also function as
activators of the kinase, we tested whether this is also the case for KIBRA. To
this end, we examined Aurora kinase activity by using the phospho-specific
antibody against the autophosphorylation sites (Thr288 for Aurora-A, Thr232 for
Aurora-B, and Thr198 for Aurora-C). As shown in Fig. 1.1A, overexpression of
KIBRA strongly stimulated Aurora-A kinase activation, as indicated by an
increase of phosphorylation of Aurora-A on Thr288. As expected, the
phosphorylation of Thr288 of Aurora-A-KD (kinase dead/inactive) form was not
increased by KIBRA. Interestingly, KIBRA S539A, a mutant that is not
phosphorylated by Aurora-A, also promoted the phosphorylation of Aurora-A on
Thr288 and did so as well as wild-type KIBRA, suggesting that Aurora-mediated
phosphorylation is not required for KIBRA to activate Aurora-A. Similarly,
overexpression of KIBRA enhanced the phosphorylation of Aurora-B on Thr232
(Fig. 1.1B). We noticed that there was still some phosphorylation of Thr232 when
Aurora-B KD was used (Fig. 1.1B, lanes 4–6), suggesting the existence of
another kinase that phosphorylated Aurora-B on Thr232.
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The expression of Aurora-A is diminished in interphase cells, whereas Aurora-A
is stabilized and activated by phosphorylation during mitosis (61). To further
explore the involvement of KIBRA in the activation of Aurora kinase, we
established doxycycline-inducible HeLa cells expressing siRNA-resistant KIBRA
or KIBRA S539A and employed a double thymidine block to synchronize these
cells in mitosis (Fig. 1.1C). As shown in Fig. 1.1D, Aurora kinases were clearly
activated in control cells (revealed by an increase of phosphorylation of Aurora-A
Thr288 and Aurora-B Thr232) 14 h after being released from the double
thymidine block (compare lane 3 with lane 1). However, activation of Aurora
kinases is largely diminished in KIBRA knockdown cells at the same time point,
indicating that KIBRA is required for full activation of Aurora kinases when cells
enter mitosis (Fig. 1.1D, compare lane 6 with lane 3). Aurora-A and cyclin B
levels are increased similarly in both control and KIBRA knockdown cells when
the cells are released into mitosis, suggesting that KIBRA knockdown did not
affect the overall entry into mitosis at the time points examined. Importantly, the
defect caused by KIBRA knockdown was completely rescued by re-expression of
either siRNA-resistant wild-type KIBRA or KIBRA S539A, further confirming that
Aurora-mediated phosphorylation is not required for KIBRA to promote activation
of Aurora (Fig. 1.1D, compare lanes 9 and 12 with lane 6). Taken together, the
data show KIBRA activates Aurora-A and -B kinases by stimulating their
autophosphorylation.
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Figure 1.1 KIBRA activates Aurora kinases.
A, various plasmids were transfected into HEK293T cells as indicated. At 48 h
after transfection, cells were lysed, and proteins were separated by SDS-PAGE
and transferred onto PVDF membranes, followed by Western blot analysis with
the indicated antibodies. In all of the figures, M(K) indicates positions where the
relevant molecular markers migrated.
B, transfection and Western blotting were done as described in A.
C, schematic diagram for D. Double thymidine block was employed as described
under “Materials and Methods.” siRNA transfection and doxycycline (DOX)
addition were done after the first thymidine block.
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D, the doxycycline-inducible HeLa cell lines expressing siRNA-resistant (siRes)
wild-type KIBRA or KIBRA S539A were established, and the cells were treated
as described in C. The samples were probed with the indicated antibodies. DT,
double thymidine block. The asterisk marks the incompletely stripped actin.
Doxycycline (Sigma) was used at 50–100 ng/ml to induce exogenous siRNAresistant KIBRA. Aur-B, Aurora-B.
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1.3.1.2 KIBRA promotes phosphorylation of Lats2 on Ser83 through
Aurora-A

Ser83 of Lats2 was shown to be phosphorylated during mitosis by Aurora-A (64).
We recently reported that KIBRA associates with both Lats2 (14) and Aurora-A
(27). These findings, along with the data from Fig. 1.1, led us to determine
whether KIBRA is involved in controlling phosphorylation of Ser83 on Lats2.
Figure 1.2A shows that enhanced expression of either KIBRA or KIBRA S539A
similarly promoted the phosphorylation of Lats2 on Ser83. However, deletion of
the WW domains (which abolishes the interaction between KIBRA and Lats2(14))
did not affect the ability of KIBRA to stimulate the phosphorylation on Ser83 of
Lats2. At this point, we reasoned that KIBRA promotes the phosphorylation of
Lats2 on Ser83 by activating Aurora-A kinase. To test this hypothesis, we
introduced Aurora-A-KD (kinase dead/inactive) or Aurora-A siRNA to determine
the role of Aurora-A in mediating the KIBRA-dependent phosphorylation of Lats2
on Ser83. As shown in Fig. 1.2, B and C, overexpression of Aurora-A-KD or
knocking down Aurora-A greatly impaired the phosphorylation of Ser83 on Lats2
induced by KIBRA, suggesting that KIBRA promotes Ser83 phosphorylation of
Lats2 by activating Aurora-A kinase and that the Aurora-A-KD form has a
dominant-negative

function.

Interestingly,

although

Aurora-A

robustly

phosphorylated Lats2 on Ser83 (Fig. 1.2B, lane 3), overexpression of Aurora-B
did not increase the phosphorylation of Lats2 on Ser83 and expression of
Aurora-B-KD had no effect on the ability of KIBRA to promote Ser83
phosphorylation of Lats2 (Fig. 1.2D).
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Because KIBRA, Aurora-A, and Lats2 associate with each other and Aurora-A is
required for KIBRA to promote Lats2 phosphorylation, we further explored
whether the interaction between KIBRA and Lats2 is Aurora-A-dependent.
Surprisingly, neither overexpression of Aurora-A nor Aurora-A knockdown
affected the association between KIBRA and Lats2 (Fig. 1.2E). In addition,
neither knockdown nor enhanced expression of KIBRA affected the interaction
between Lats2 and Aurora-A (Fig. 1.2F). These data suggest that KIBRA,
Aurora-A, and Lats2 interact with each other in an independent or mutually
exclusive manner.
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Figure 1.2 KIBRA promotes phosphorylation of Lats2 on Ser83 through
Aurora-A.
A, Myc-tagged Lats2 was transfected into HEK293T cells with FLAG-tagged
KIBRA or KIBRA mutants as indicated. At 48 h after transfection, cells were lysed,
and proteins were immunoprecipitated with Myc antibody followed by Western
blot analysis with the indicated antibodies. Lysates were also probed with FLAG
antibody to check the expression of transfected KIBRA.
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B, HEK293T cells were transiently transfected with plasmids as indicated. At 48 h
after transfection, Myc-Lats2 was immunoprecipitated and probed with p-Lats2
Ser83 and Myc antibodies. Lysates without immunoprecipitation were also
probed with FLAG and GFP antibodies to check the expression of KIBRA and
Aurora-A (Aur-A).
C, HEK293T cells were transiently transfected with control siRNA (lanes 1 and 2)
or

siRNA

against

Aurora-A

(lane

3)

and

plasmids

as

indicated.

Immunoprecipitation and Western blotting were done as described in B.
D, transfection, immunoprecipitation, and Western blot analysis were performed
as described in B except GFP-Aurora-B and GFP-Aurora-B-KD were used.
E, HEK293T cells were transiently transfected with control siRNA (lanes 1–3) or
siRNA against Aurora-A (lane 4) and plasmids as indicated. At 48 h posttransfection, cells were lysed and immunoprecipitated with FLAG antibody. The
immunoprecipitates were probed with the indicated antibodies. Total cell lysates
were used to check the expression of Aurora-A and Myc-Lats2.
F, HEK293T cells were transiently transfected with control siRNA (lanes 1–3) or
siRNA targeting KIBRA and various plasmids as indicated. Cells were harvested
at 48 h post-transfection. The immunoprecipitates and total cell lysates without
immunoprecipitation were probed with the indicated antibodies. HC, IgG heavy
chain. M(K) indicates positions where the relevant molecular markers migrated.
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1.3.1.3 Lats2 overexpression enhances KIBRA mobility
During our experiments, we noticed the migration of KIBRA increased on SDS
gels when Lats2 was overexpressed ((14); Fig. 1.3A, compare lane 2 with lane 1).
The kinase activity and Aurora-A-mediated phosphorylation on Ser83 were not
required for this function of Lats2 (Fig. 1.3A, compare lanes 2–4 with lane 1).
Interestingly, Lats2, but not Mst1 or its close homolog Lats1, possessed this
function (Fig. 1.3A, compare lanes 5 and 6 with lanes 2–4), confirming the
specificity. To further explore which domain/region is required for Lats2 to
enhance the mobility of KIBRA, we generated a series of truncated Lats2
constructs (Fig. 1.3B). Deletion of the C-terminal 400 amino acids did not
significantly alter the ability of Lats2 to enhance the mobility of KIBRA (Fig. 1.3C).
However, deletion of an additional 100 amino acids abolished the ability of Lats2
to increase the mobility of KIBRA, suggesting that the region encompassing
amino acids 588–689 is required for Lats2 to perform this function. Additional
truncated constructs were made with deletions within this region, and our data
suggest that the highly conserved region (amino acids 598–619 of human Lats2,
Fig. 1.3B) is required for Lats2 to enhance the mobility of KIBRA (Fig. 1.3D).
Internal deletion of these 22 amino acids in Lats2 (Lats2Δ22) largely abolished its
function to increase KIBRA mobility (Fig. 1.3E).
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Figure 1.3 Overexpression of Lats2 enhances mobility shift of KIBRA.
A, HA-tagged KIBRA was transfected into HEK293T cells with empty vector or
various DNAs as indicated. At 48 h post-transfection, total cell lysates were
probed with the indicated antibodies.
B, schematic diagram of various Lats2 constructs used for C--E.
C–E, FLAG-tagged KIBRA was transfected into HEK293T cells with empty vector
or plasmids as indicated. At 48 h post-transfection, total cell lysates were probed
with the indicated antibodies. M(K) indicates positions where the relevant
molecular markers migrated.

25

1.3.1.4 Lats2 inhibits phosphorylation of KIBRA on Ser539

We previously reported that during mitosis Ser539 of KIBRA is phosphorylated
by Aurora kinases and that KIBRA migrates differently on SDS-polyacrylamide
gels depending on its phosphorylation status (27). Thus, we tested whether
expression of Lats2 might inhibit the phosphorylation of KIBRA using phosphospecific antibodies. Overexpression of Lats2, but not Lats2Δ22, strongly
decreased the phosphorylation of KIBRA on Ser539 (Fig. 1.4A). In addition,
knockdown of Lats2 increased the phosphorylation of transfected KIBRA on
Ser539 (Fig. 1.4B). Taken together, these data suggest that during mitosis Lats2
antagonizes Aurora-mediated phosphorylation of KIBRA on Ser539.

We recently reported that PP1 can dephosphorylate Ser539 of KIBRA (27). Thus,
we explored whether PP1 is required for the Lats2-dependent reduction of
phosphorylation of KIBRA Ser539. As shown in Fig. 1.4C, in the presence of
siRNA against PP1c (catalytic subunit), Lats2 inhibited the phosphorylation of
KIBRA on Ser539 less efficiently (compare lane 3 with lane 2), indicating that
Lats2 may inhibit KIBRA phosphorylation on Ser539, at least partially through
regulating PP1c.
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Figure 1.4 Lats2 inhibits the phosphorylation of KIBRA on Ser539 via PP1.
A, HEK293T cells were transfected with FLAG-KIBRA and plasmids as indicated.
At 48 h post-transfection, the cells were lysed and immunoprecipitated with
FLAG antibody. The immunoprecipitates were probed with anti-phospho-Ser539
KIBRA and subsequent anti-FLAG antibodies.
B, HeLa cells were transfected with FLAG-KIBRA and control siRNA (lane 1) or
siRNA against Lats2 (lane 2) for 48 h. FLAG-KIBRA was immunoprecipitated and
probed

with

the

indicated

antibodies.

Total

cell

lysates

without

immunoprecipitation were also analyzed.
C, HeLa cells were transfected with control siRNA (lanes 1 and 2) or siRNA
targeting PP1 (lane 3) and plasmids as indicated. FLAG-KIBRA was
immunoprecipitated and probed with phospho-KIBRA Ser539 and subsequent
anti-FLAG antibodies. Total cell lysates without immunoprecipitation were also
analyzed. M(K) indicates positions where the relevant molecular markers
migrated.
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1.3.1.5 KIBRA knockdown causes mitotic defects

We found that KIBRA activates the important mitotic kinase, Aurora-A (Fig. 1.1).
Moreover, KIBRA is a verified substrate of both Aurora- A and -B. Therefore, we
expected KIBRA to play an important role in the process of mitosis. To test the
function of KIBRA in mitosis, we knocked down KIBRA in both MCF-7 and HeLa
cells using two different siRNA oligonucleotides. As seen in Fig. 1.5A, 48 h after
transfection, both oligonucleotides efficiently depleted KIBRA in HeLa as well as
MCF-7

cells.

We

first

depleted

KIBRA

in

MCF-7

cells

and

used

immunofluorescence to identify any mitotic defects. The depletion of KIBRA in
MCF-7 cells caused striking defects in spindle assembly (Fig. 1.5B and C) as
well as the centrosome number (Fig. 1.5B and D). KIBRA activates Aurora-A and
Aurora-A activity is known to be required for proper spindle assembly and
centrosome function. Hence, it is likely for these reasons that depleting KIBRA
caused defects in spindle assembly and centrosome number. We observed that
the knockdown of KIBRA strongly affected the spindle structure (Fig. 1.5B). The
spindle microtubules were abnormally organized in KIBRA siRNA cells (Fig. 1.5B,
middle panels). Furthermore, the centrosomes appeared fragmented (Fig. 1.5B,
lowest panels). About 48% of the cells that were transfected with KIBRA siRNA-1
and 35% of the cells that were transfected with KIBRA siRNA-2 displayed
abnormally assembled metaphase spindles (Fig. 1.5C). Furthermore, 38% of the
cells that were transfected with KIBRA siRNA-1 and >33% of the cells that were
transfected with KIBRA siRNA-2 exhibited defects in centrosome numbers (Fig.
1.5D). These data show that KIBRA plays a crucial role in mitosis by regulating
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centrosome function and spindle assembly, possibly via regulating Aurora-A
activity.

Because we detected abnormal spindles in KIBRA siRNA MCF-7 cells, we
expected that the knockdown of KIBRA would also impair chromosome
alignment during mitosis. To test this hypothesis, HeLa cells were transfected
with either a scrambled, non-targeting siRNA or with siRNA against KIBRA.
Furthermore, these cells were either treated with dimethyl sulfoxide (control) or
with monastrol (an Eg5 inhibitor that arrests cells in mitosis). The monastrol was
then washed out, and the cells were allowed to proceed normally through mitosis
(65, 66). All cells were then subjected to immunofluorescence analysis to
visualize abnormalities in chromosome alignment. Remarkably, the depletion of
KIBRA from HeLa cells caused the appearance of lagging chromosomes (Fig.
1.6A, panel iv), chromosome bridges (Fig. 1.6A, panel v), and micronuclei (Fig.
1.6A, panel vi) during different stages of mitosis. Additionally, we observed that
the knockdown of KIBRA by another siRNA in HeLa cells also yielded abnormal
metaphase chromosome alignment (Fig. 1.6B). In addition, we observed that the
enrichment of mitotic cells by monastrol treatment further increased the
percentage of cells with lagging chromosomes that were obtained upon
knockdown of KIBRA (Fig. 1.6C). All these data establish a very important role
for KIBRA for the proper progression of mitosis.
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Figure 1.5 KIBRA knockdown causes mitotic defects in MCF-7 cells.
A, MCF-7 and HeLa cells were treated with control siRNA (20 nm, lanes 1 and 4)
and siRNA targeting KIBRA (20 nm, lanes 2, 3, 5, and 6) for 48 h, and
knockdown efficiency was analyzed by Western blotting.
B, MCF-7 cells were transfected with KIBRA siRNA. At 24–48 h post-transfection,
cells were fixed, permeabilized, and stained (see “Experimental Procedures”)
with antibodies as indicated. Representative confocal images are shown. Scale
bar, 10 μm.
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C, quantification of spindle defects in KIBRA knockdown cells. The graph
represents the percentage of cells from three independent experiments, and at
least 150 mitotic cells were counted in each group. Error bars represent S.E. **, p
< 0.01; *, p < 0.05(t test).
D, quantification of centrosome defects in KIBRA knockdown cells. The graph
represents the percentage of cells from three independent experiments, and at
least 150 mitotic cells were counted in each group. Error bars represent S.E. **, p
< 0.01; *, p < 0.05(t test). M(K) indicates positions where the relevant molecular
markers migrated.
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Figure 1.6 KIBRA knockdown causes chromosome misalignment in HeLa
cells.
A and B, HeLa cells were transfected with the siRNA oligonucleotides as
indicated (20 nm). At 48 h post-transfection, cells were treated with monastrol (an
Eg5 inhibitor that arrests cells in mitosis) for 2 h. The monastrol was then washed
out, and the cells were allowed to proceed normally through mitosis (65, 66).
These cells were then fixed and stained with α-tubulin antibody. DAPI was used
to visualize the DNA. Cells at various mitotic phases are shown. Yellow arrows
mark the abnormalities in KIBRA knockdown cells. Scale bar, 10 μm.
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C, Quantification of chromosome misalignment (lagging chromosome) in KIBRA
knockdown cells. The graph represents the percentage of cells from three
independent experiments, and at least 150 mitotic cells were counted in each
group. Error bars represent S.E. **, p < 0.01; *, p < 0.05(t test).
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1.3.2 CDK1 Phosphorylation of TAZ in Mitosis Inhibits its Oncogenic
Activity.
1.3.2.1 TAZ is phosphorylated during anti-mitotic drug-inducedG2/M arrest
We and others showed that TAZ protein is upshifted on SDS-polyacrylamide gels
during Taxol or nocodazole (both agents arrest cells in G2/M) -induced mitotic
arrest (59, 60). As shown in Figure 7A, the dramatic mobility up-shift of TAZ was
readily detected by a phos-tag gel (Fig. 1.7A).Lambda phosphatase treatment
converted all slow-migrating bands to fast-migrating bands, confirming that the
mobility shift of TAZ during G2/M is caused by phosphorylation (Fig. 1.7B). Since
TAZ is a paralog of YAP and mitotic phosphorylation of YAP is mediated by the
mitotic kinase CDK1, we tested whether CDK1 is also responsible for TAZ
phosphorylation. As shown in Figure 7C, both RO3306 (a CDK1 inhibitor) and
Purvalanol A (an inhibitor for CDK1 and other CDKs) completely reverted the
mobility shift of TAZ, suggesting that CDK1 is likely to be responsible for TAZ
phosphorylation. Inhibition of other mitotic kinases Aurora-A, B, C (with VX-680)
and PLK1 (with BI2536) did not alter the TAZ phosphorylation (data not shown).

1.3.2.2 CDK1 phosphorylates TAZ in vitro
Next, we determined whether CDK1 kinase can directly phosphorylate TAZ in
vitro with His-tagged TAZ as substrates. Figure 1.7D shows that Taxol-treated
mitotic lysates robustly phosphorylated TAZ and that CDK1 inhibitors greatly
reduced

phosphorylation

of

His-TAZ

(Fig.

1.7D).

Furthermore,

purified
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CDK1/cyclin B complex phosphorylated His-TAZ in vitro (Fig. 1.7E). These
results indicate that CDK1 phosphorylated TAZ in vitro.

There are a total of six sites that fit the proline-directed consensus sequence of
CDK1-phosphorylation sites(67). Two of them (threonine 175 and threonine 285)
do not exist in mouse and rat and are excluded for further study. Interestingly, the
remaining four sites (serine 90, serine 105, threonine 326, and threonine 346)
have been identified as mitotic phosphorylation sites from large scale proteomic
studies(68). Mutating these four sites to non-phosphorylatable alanines (TAZ4A) almost completely abolished the
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P incorporation into TAZ, suggesting that

S90, S105, T326 and T346 are the main CDK1 phosphorylation sites (Fig. 1.7F).
Metabolic labeling confirmed that wild type TAZ was phosphorylated during
Taxol-treatment and TAZ-4A was not able to be further phosphorylated during
Taxol-induced G2/M arrest (Fig. 1.7G), indicating that these four sites are the
main phosphorylation sites during G2/M in cells.

1.3.2.3 CDK1/cyclin B complex phosphorylates TAZ at S90 and S105 in vitro
We have generated phospho-specific antibodies against S90, S105, T326, and
T346. Using these antibodies we demonstrated that CDK1 phosphorylated TAZ
atS90 and S105 in vitro (Fig. 1.7H,I). Addition of RO3306 abolished the
phosphorylation (Fig. 1.7H,I). We could not detect a signal when anti-p-TAZ T326
and T346 antibodies were used with these conditions (data not shown).
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Figure 1.7 TAZ is phosphorylated by CDK1 during G2/M arrest.
A, HeLa cells were treated with DMSO (control), Taxol (0.1 µM for 16 h) or
Nocodazole (Noco, 100 ng/ml for 16 h). Total cell lysates were probed with the
indicated antibodies.

O

marks the non-phosphorylated TAZ; * and ** mark the

phosphorylated TAZ.
B, HeLa cells were treated with Nocodazole (Noco) as indicated and cell lysates
were further treated with (+) or without (-) λ phosphatase (ppase). Total cell
lysates were probed with anti-TAZ antibody.
C, HeLa cells were treated with Nocodazole (Noco). RO3306 (CDK1 inhibitor) or
Purvalanol A (CDKs inhibitor) were added (with or without MG132) into the cells
2 h before harvesting the cells. Proteasome inhibitor MG132 was also added
(together with inhibitors) to prevent cyclin B from degradation and cells from
exiting from mitosis.Total cell lysates were subjected to Western blotting with the
indicated antibodies.
D, In vitro kinase assays using HeLa cell lysates to phosphorylate recombinant
His-TAZ in the presence of
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P. Asy: asynchronized; Tax: Taxol-treated.The

samples were also probed with cyclin B and β-actin antibodies.
E, In vitro kinase assays with purified CDK1/cyclin B complex. RO3306 (5 µM) or
Purvalanol (10 µM) was used to inhibit CDK1 kinase activity.
F, In vitro kinase assays with purified CDK1/cyclin B complexto phosphorylate
recombinant His-TAZ or His-TAZ-4A.
G, GFP-tagged TAZ or –TAZ-4A were transfected into HeLa cells. At 24 h posttransfection, cells were treated with nocodazole (Noco) for 16 h and metabolically
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labeled in the presence of

32

P for an additional 2 h as we previously

described(58).
H,I, In vitro kinase assays were done as in E except anti-phospho-TAZS90 and
S105 antibodies were used.
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1.3.2.4 Phosphorylation of TAZ occurs in cells during normal mitosis
Next, we performed immunofluorescence microscopy with these phosphospecific antibodies. Strong and specific signals were detected in nocodazolearrested prometaphase cells for all antibodies against S90, S105, T326, and
T346 (Fig. 1.8A-D, top panels, red arrows). Very weak or no signal was detected
in interphase cells (Fig. 1.8A-D, yellow arrows). Importantly, phosphopeptide-,
but not non-phosphopeptide- (control peptide), incubation largely blocked the
signal, suggesting that these antibodies specifically recognize phosphorylated
TAZ (Fig. 1.8A-D, middle panels). Addition of RO3306 largely abolished the
signals detected by p-TAZS90, S105, T326, and T346 antibodies in
prometaphase cells, further indicating that the phosphorylation is CDK1
dependent (Fig. 1.8A-D, low panels).

To further investigate the dynamics of TAZ phosphorylation in cells during
unperturbed/normal mitosis, we utilized double thymidine block and release and
determined the phospho-status of TAZ during different cell-cycle phases. We
found that the p-TAZS90 signal was readily detectable in prophase and peaked
in prometaphase/metaphase. The signal was then weakened in anaphase and
further diminished in telophase and cytokinesis (Fig. 1.9A). We observed similar
staining patterns when the p-TAZ S105, T326, and T346 antibodies were used
for staining (Fig. 1.9B,C and data not shown). These data strongly indicate that
mitotic phosphorylation of TAZ occurs dynamically in cells.
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Figure 1.8 TAZ is phosphorylated at multiple sites by CDK1 during
nocodazole-arrested G2/M phase.
A, HeLa cells were treated with nocodazole for overnight and fixed. The cells
were then incubated with or without peptides used for immunonizing rabbits prior
to phospho-TAZ S90 staining. CDK1 inhibitor (RO3306) was added 2 h before
the cells were fixed (bottom low).
B-D, Similar experiments were done as in A with different phospho-specific
antibodies. Red and yellow arrows mark some of the prometaphase cells and the
interphase cells, respectively.
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Figure 1.9 TAZ is phosphorylated at S90, S109, T326 and T346 during
normal mitosis.
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A,B, HeLa cells were synchronized by a double thymidine (DT) block and release
method. Cells were stained with p-TAZ S90 (A) and p-TAZS105 (B).Cells were
co-stained with DAPI and β-tubulin to indicate the various phases.
C, HeLa cells were synchronized as in (A) and stained with DAPI, phosphospecific antibodies against TAZ, and β-tubulin. A lower power (40X) objective
lens was used for photography to view various phases of the cells in a field. Red
and yellow arrows in (C) mark the mitotic and interphase cells, respectively.
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1.3.2.5

Mitotic

phosphorylation

inhibits

TAZ

in

EMT

and

cellular

transformation
We next examined the biological significance of mitotic phosphorylation of TAZ.
Overexpression of TAZ promotes epithelial-mesenchymal transition (EMT) and
transforms MCF10A cells (51, 69). We first established pooled cell lines stably
expressing TAZ or TAZ mutants (Fig. 1.10A). We confirmed that the epithelial
marker E-cadherin was downregulated and vimentin (a mesenchymal marker)
was greatly upregulated in cells expressing active TAZ (TAZ-S89A) (Fig. 1.10A).
Interestingly,

TAZ-4A

(non-mitotic

phosphorylatable

mutant)

possesses

higheractivity in regulating EMT in MCF10A cells when compared to wild type
TAZ (Fig. 1.10A,B). In contrast, ectopic expression of TAZ-4D (a mitotic
phosphomimetic mutant) failed to alter EMT in MCF10A cells (Fig. 1.10A,B).
Mutating phosphorylation sites to alanines (TAZ-S89A/4A) further increased
TAZ-S89A activity in promoting EMT (Fig. 1.10A,B), suggesting that mitotic
phosphorylation inhibits TAZ in EMT. Consistent with the EMT results, we
observed significant morphology change of MCF10A cells expressing TAZ-4A,
but not vector, wild type TAZ or TAZ-4D (Fig. 1.10C). Again, the most significant
change was observed in TAZ-S89A/4A-expressing cells (Fig. 1.10A-C).

MCF10A cells expressing TAZ-S89A/4A formed colonies in soft agar, however,
all other cells failed to produce any obvious colonies when fewer cells were
seeded (Fig. 1.10D). Again, TAZ-S89A/4Apossesses higher activity compared to
TAZ-S89A in stimulating anchorage-independent growth in soft agar (Fig.
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1.10E,F). TAZ, TAZ-4A or TAZ-4D overexpression failed to produce colonies in
soft agar even when 10,000 cells were seeded (data not shown). Similarly, only
TAZ-S89A/4A-expressing HPNE (an immortalized pancreatic epithelial cell line)
cells were able to produce colonies in soft agar (Fig. 1.10G-I). Together, these
data strongly suggest that mitotic phosphorylation inhibits TAZ-mediated cellular
transformation in immortalized epithelial cells.
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Figure 1.10 Mitotic phosphorylation of TAZ inhibits EMT and anchorageindependent growth.
A, Establishment of MCF10A cells stably express vector, TAZ, TAZ-S89A, TAZ4A, TAZ-4D, and TAZ-S89A/4A (TAZ-5A).4A: S90A/S105A/T326A/T346A; 5A:
S89A/4A; 4D: S90D/S105D/T326D/T346D. The total cell lysates were probed
with the indicated antibodies.
B, Immunofluorescence staining with E-cadherin inMCF10A cells established in
A.
C, Morphology change of MCF10A cells expressing vector or various TAZ
mutants.
D-F, Colony assays in soft agar (anchorage-independent growth) in MCF10A
cells established in A.
G, Establishment of HPNE cells stably express vector, TAZ-S89A, TAZ-5A
(S89A/4A).
H,I, Colony assays in HPNE cells established in G.
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1.3.2.6

Mitotic

phosphorylation

of

TAZ

impairs

cell

motility

and

transcriptional activity
Several studies showed that TAZ/TAZ-S89A also promotes cell migration,
invasion and metastasis in animal (70, 71). We therefore tested whether mitotic
phosphorylation affects TAZ’s activity in cell motility. As expected, ectopic
expression of TAZ or TAZ-S89A increased migration of MCF10A cells assayed
by wound healing (Fig. 1.11A). Mutating CDK1-mediated phosphorylation sites to
alanines (TAZ-4A) increased migration to a greater extent when compared to
wildtype TAZ (Fig. 1.11A). In contrast, cells expressingTAZ-4D possess much
lower migratory activity than cells expressing wild type TAZ (Fig. 1.11A). Cells
expressing TAZ-S89A/4A migrate the fastest (Fig. 1.11A). We further examined
the TAZ activity in invasion using Matrigel. Expression of TAZ-S89A greatly
enhanced invasion of both MCF10A (Fig. 1.11B,C) and HPNE (Fig. 1.11D,E)
cells. In line with the observations from Fig. 1.10 and Figure 10A, non-mitotic
phosphorylatable mutant (TAZ-S89A/4A) further increased the invading activity
when compared to TAZ-S89A (Fig. 1.11B-E). Again, TAZ-4D-expressing cells
(similar to control cells) possess the lowest activity in invasion (data not shown).
Together, these data suggest that mitotic phosphorylation of TAZ inhibits cell
motility in immortalized epithelial cells.

TAZ is a transcriptional co-activator, and functions mainly through the TEAD1-4
transcription factors in the Hippo pathway (69, 72, 73). We determined whether
mitotic phosphorylation affects TAZ’s transcriptional activity using luciferase
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reporter assays. As shown in Figure 5F, expression of TAZ-5A (TAZ-S89A/4A)
significantly increased the luciferase activity compared with TAZ-S89A (Fig.
1.11F). Expression of TAZ-4D failed to significantly induce TEAD-luciferase
activity (data not shown). These results suggest that mitotic phosphorylation
impairs TAZ’s transcriptional activity. Consistent with these observations, the
target genes expression was further induced by overexpression of TAZ-5A when
compared with TAZ-S89A (Fig. 1.11G).Collectively, these data strongly indicate
that mitotic phosphorylation inhibits TAZ’s oncogenic activity.
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Figure 1.11 Mitotic phosphorylation of TAZ inhibits its oncogenic and
transcriptional activity.
A, Wound healing assays in MCF10A cells expressing various TAZ constructs.
B,C, Cell invasion assays with MCF10A cells expressing vector, TAZ-S89A or
TAZ-S89A/4A. Invaded cells were stained with DAPI and representative fields
were shown (C).
D,E, Cell invasion assays with HPNE cells expressing vector, TAZ-S89A or TAZS89A/4A. Invaded cells were stained with DAPI and representative fields were
shown (E).
F, Luciferase reporter assays in HEK293T cells. Expression levels of TAZ-S89A
and TAZ-S89A/4A are similar in all transfections (data not shown). Ctrl: control
(empty vector); 5A: S89A/4A. Data are expressed as the mean ± s.e.m. of three
independent experiments (each in triplicate). **: p<0.01 (TAZ5A vs TAZ-S89A)(ttest).
G, Quantitative RT-PCR of YAP targets in MCF10A cells expressing vector, TAZS89A or TAZ-S89A/4A. Data are expressed as the mean ± s.e.m. of three
independent experiments (in duplicate). ***: p< 0.001; **: p< 0.01 (TAZ5A vs
TAZ-S89A) (t-test).
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1.3.2.7 Non-phosphorylatable (active) TAZ induces mitotic abnormalities
We next examined whether TAZ or its phosphorylation mutants are able to
trigger mitotic defects. MCF10A cells stably expressing vector, TAZ-S89A, and
TAZ-5A (TAZ-S89A/4A) were used for this purpose. Consistent with our recent
studies, immunofluoresence staining with α-tubulin and γ-tubulin showed normal
microtubule/spindle formation and centrosome number during mitosis in most
control cells (Fig. 1.12A). In contrast, mitotic abnormalities (disorganization of
microtubules and formation of multipolar spindles) were detected in a significantly
higher percentage of cells expressing TAZ-S89A, and to a greater extent in TAZS89A/4A-expressing cells (Fig. 1.12A,B). Overexpression of TAZ-S89A or TAZS89A/4A also induced abnormal centrosome (γ-tubulin staining) number (Fig.
1.12A,C). Not surprisingly, massive chromosome misalignment and chromosome
missegregation were observed in a higher percentage of TAZ-S89A- or TAZS89A/4A-expressing cells when compared with vector-expressing cells (Fig.
1.12A,D). These data suggest that ectopic expression of non-phosphorylatable
(active) TAZ is sufficient to trigger mitotic abnormalities in immortalized epithelial
cells.
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Figure 1.12 Non-phosphorylatable TAZ induces mitotic defects in MCF10A
cells.
A, Representative photos of normal mitosis (vector control) and mitotic
abnormalities (TAZ-S89A or TAZ-S89A/4A) in MCF10A cells. MCF10A cells
stably expressing vector, TAZ-S89A, and TAZ-S89A/4A (TAZ5A) were
established at the same time and maintained at similar passage (around 22-24 at
the time of experiments conducted).Cells were stained with α-tubulin, γ-tubulin
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antibodies and DAPI to visualize microtubules (red), centrosomes (green), and
chromosomes (blue), respectively.
B-D,

Quantification

of

mitotic

characteristics

including

microtubule

organization/multipolar spindles. (B), centrosome number (C), and chromosome
alignment. (D). Data were collected from n=106,185, and 243 mitotic cells for
vector control, TAZ-S89A, and TAZ-S89A/4A-expressing cells, respectively. Data
were expressed as the mean ± s.e.m. of four independent experiments. **: p<
0.01; *: p<0.05 (t-test).
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Discussion

Aurora kinases are important regulators of cell cycle progression and are
potential oncogenes (74, 75). Thus, identification of modulators and/or substrates
of Aurora kinases is important for understanding the function and mechanisms of
action of Aurora kinase family proteins and the basic principles of cell cycle
regulation. In fact, many regulators or substrates of Aurora kinase have been
implicated in controlling mitotic entry, chromosome alignment/segregation, and
cytokinesis (76). We previously showed that KIBRA is phosphorylated by Aurora
kinases in mitosis (27). In the present study, we have further demonstrated that
KIBRA is required for full activation of Aurora kinases during mitosis (Fig. 1.1).
Future studies are needed to examine whether Aurora-mediated phosphorylation
of KIBRA is involved in the mitotic defects induced by knocking down KIBRA.

Both Aurora-A and Lats2 are localized to the centrosome during mitosis, raising
the possibility that KIBRA or phosphorylated KIBRA is also localized to this
mitotic structure, but this has not been investigated and demonstrated.
Interestingly, a previous report showed that KIBRA associates with the
microtubule motor protein dynein light chain 1 (24). These findings, along with
the demonstration of mitotic defects induced by KIBRA knockdown, strongly
suggest that KIBRA may also be required for proper construction of the mitotic
apparatus. We are currently investigating the spatial and temporal localization of
KIBRA and phosphorylated KIBRA, and such studies are anticipated to further
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strengthen the importance of KIBRA in cell cycle progression, especially in
mitosis.

The mechanism through which Lats2 regulates KIBRA phosphorylation is
currently unknown. Phosphorylation of KIBRA on Ser539 is regulated by Aurora
kinase and PP1. Thus, it is possible that overexpression of Lats2 stimulates
dephosphorylation of KIBRA by inhibiting Aurora kinase activity and/or activating
PP1. However, although we showed that PP1 is required for Lats2 to inhibit
phosphorylation of KIBRA on Ser539 (Fig. 1.4), a solid connection between Lats2
and PP1 has not been established. We previously demonstrated that KIBRA also
associates with PP1 (27). Therefore, it will be interesting to explore whether
Lats2 or Lats2Δ22 affects PP1 activity or the interaction between KIBRA and
PP1. Moreover, it is of particular interest to determine the difference between
Lats2

and

Lats1

with

regards

to

their

activity toward

inhibiting

the

phosphorylation of KIBRA.

We noticed that cells with Lats2 knockdown or knock-out also exhibit defects
similar to those caused by knocking down KIBRA, including failure of centrosome
maturation, spindle disorganization, and chromosome misalignment, which
further supports the notion that KIBRA-Aurora-Lats2 may form a novel signaling
axis that regulates mitosis. It will be interesting to explore to what extent these
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proteins regulate mitosis in a mutually dependent way. Interestingly, recent
reports have also connected other members of the Hippo pathway with mitosis.
For example, the tumor suppressors Mst1 and Mob1 are involved in centrosome
duplication, and Mob1 also localizes to the centrosome during mitosis (77).
WW45 and Mst2 control centrosome disjunction and the localization of Nek2 to
centrosomes (78). In addition, Mats (Drosophila ortholog of Mob1) is required for
proper chromosomal segregation in developing embryos (79). Thus, it may be a
common feature that Hippo pathway components control mitotic-related events
and that deregulation of their function may result in mitotic defects, contributing to
genome instability/aneuploidy and subsequent tumorigenesis. One would expect
that YAP and TAZ, downstream effectors in the Hippo pathway, may also have a
mitotic role. Therefore, it is worth investigating whether Hippo pathway activity is
cell cycle-regulated.

Intriguingly, recent studies have shown that most of the Hippo core tumor
suppressor proteins, such as Mst1/2, Lats1/2, WW45, Mob1 are involved in
regulating mitosis (9, 78, 80, 81). Furthermore, several other regulators of the
Hippo pathway, such as Ajuba, Zyxin, as well as the effector YAP are known to
be regulated (phosphorylated) during mitosis and they all play a role in mitotic
progression (27, 58, 59, 61, 82-86). Therefore, these studies suggest that the
Hippo-YAP/TAZ pathway ensures normal mitosis and deregulation of the
pathway causes mitotic aberrations and tumorigenesis.
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Upon treatment with anti-microtubule agents including Taxol, YAP (59, 60) and
KIBRA (27, 58) are phosphorylated by mitotic kinases independently of the Hippo
pathway. Another prominent change is the marked increase of Lats2 proteins in
response to Taxol treatment (59, 87). Interestingly, induction of Lats2 and
phosphorylation of YAP regulate Taxol-sensitivity in cancer cells (60, 87).
Furthermore, TAZ and its downstream targets Cyr61 and CTGF have been
shown to be important regulators for Taxol-resistance in breast cancer cells (60).
Our current studies showed that TAZ is phosphorylated during Taxol treatment
and this phosphorylation inhibits its transcriptional activity (Figs. 1.7,11). Taxol
(trademark: Paclitaxel) is widely used for treating breast and ovarian cancer
patients and drug-resistance is one of the major clinical challenges. Therefore, it
will be interesting to determine the role of mitotic phosphorylation of TAZ in
mediating anti-Taxol drug resistance.

Although recent studies have demonstrated the important roles for TAZ in
promoting tumorigenesis, the underlying mechanisms are largely unclear. The
current study identified novel phosphorylation of TAZ during mitosis and
importantly, the mitotic phosphorylation regulates TAZ’s oncogenic activity (Figs.
1.10,11). Interestingly, TAZ-5A (a non-phosphorylatable mutant), but not TAZ-4D
(L.Z. and J.D., unpublished observations), drives massive mitotic defects (Fig.
1.12). Thus, TAZ may contribute to cancer development by regulating mitosisrelated

events,

since

aberration

of

mitosis

often

instability/aneuploidy and subsequent tumor formation (88).

causes

genome
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Our data not only reveal a new layer of regulation for TAZ’s oncogenic activity,
but also highlight a previously unrecognized mechanism through which TAZ
exerts its oncogenic function.

We found that mitotic phosphorylation did not

affect TAZ’s binding with the major transcription factor TEAD1 and Lats2 kinase
(L.Z. and J.D., unpublished observations). Thus, it is not clear how CDK1
phosphorylation of TAZ increases its transcriptional activity. Does this
phosphorylation regulate TAZ’s transcriptional activity with other transcription
factors? We recently found that YAP (a paralog of TAZ) is required for the
spindle checkpoint activation induced by Taxol (82). YAP regulates the spindle
checkpoint through upregulating the spindle checkpoint protein BubR1 in a
mitotic phosphorylation-dependent manner (82). Since the spindle checkpoint is
a surveillance mechanism in mitosis (89), these studies suggest that YAP and its
mitotic phosphorylation trigger mitotic defects through the dysregulation of the
spindle checkpoint machinery. Surprisingly, knockdown of TAZ had no effects on
the spindle checkpoint activation and mitotic arrest in the presence of anti-mitotic
agents (L.Z. and J.D., unpublished observations), suggesting a distinct function
of TAZ and YAP in mitosis. Future studies are needed to address how TAZ and
its mitotic phosphorylation are involved in mitosis and how they promote the
mitotic defects. Furthermore, mitotic phosphorylation activates YAP (59) and in
contrast, TAZ is inhibited by mitotic phosphorylation regarding their oncogenic
activity (Figs. 1.10,11). It is currently not known how TAZ and YAP achieved
opposite regulation (negatively and positively, respectively) during mitosis by the
same kinase.
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Chapter 2

Functional Study of Hippo-YAP Signaling in Prostate Cancer
This part is a modified version of the original publication:
Mol Cell Biol. 2015 Apr 15;35(8):1350-62.
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2.1 Introduction
In 2014, there were 233,000 estimated new cases of prostate cancer and 29，
480 estimated deaths caused by prostate cancer in the United States. In the past
10 years, prostate cancer remains the most common malignancy and the second
leading cause of cancer deaths among men in the United States. The treatment
regimens of prostate cancer are based on the stage of the disease. For localized
cancer, the conventional treatments are surgical excision (radical prostatectomy)
and radiotherapy. In cases of advanced or invasive cancer, including those have
metastatic lesions, androgen deprivation therapy is the major strategy (1).
Androgen ablation initially decreases the volume of both primary and metastatic
lesions and reduces PSA to low or undetectable level, however, in most cases
the tumors will recur and become chemotherapy-resistant and androgenindependent (2, 3). This recurrence of prostate cancer is termed “castration
resistant prostate cancer (CRPC)”, since the removal of testicular androgen by
chemical or surgical castration does not effect as in the initial response,
ultimately the disease will be lethal (4, 5).

Circulating androgens are essential for both normal prostate development and
the onset of prostate cancer through interactions with the androgen receptor
(AR). Testosterone is the major androgen produced by testis and adrenal gland.
When testosterone enters prostate cells, it is converted to dihydrotestosterone
(DHT) by the enzyme 5-reductase. This more potent form of androgen binds to
the AR and induces its dimerization and phosphorylation. Then the androgen
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receptor complex translocates into nucleus, where it binds to androgen-response
elements in the promoter regions of target genes, and leads to biological
responses including growth, survival and the produce of prostate-specific antigen
(PSA).

During castration-resistant progression, prostate cancer relies on various cellular
pathways, some involving the androgen receptor and others bypassing it. In the
former type of pathway, amplification of AR gene copy number happens in about
one-third of CRPC patients (6-8). Another 10%–30% of tumors have mutations of
AR that may confer increased protein stability, greater sensitivity to androgens,
novel responses to other steroid hormones, ligand-independent activity, or
increased recruitment of AR coactivator proteins (9-11). In the pathways that
bypass the androgen receptor, the loss of PTEN (phosphatase and tensin
homolog) results in up-regulation of the Akt/mTOR signaling pathway in prostate
cancer, primarily through activation of Akt1 (12, 13). In addition, Erk-MAPK
signaling is also frequently activated in prostate cancer, particularly in advanced
disease, and is often coordinately deregulated together with Akt signaling (14,
15).

In the past two decades, the use of genetically engineered transgenic and
knockout mice has represented a major progress of prostate cancer
investigations. A well-studied model is the TRAMP (transgenic adenocarcinoma
of the prostate) mouse model, which carries a probasin promoter driving both
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SV40 large T and small t antigen and results in adenocarcinoma and CRPC (16).
Loss of Nkx3.1 and Pten showed accelerated formation of high-grade PIN
(prostate intraepithelial neoplasia) and invasive cancer (17). Conditional deletion
of PTEN and p53 in the prostate driven by a minimal probasin promoter driving
Cre recombinase developed PIN and adenocarcinoma. However, none of these
models closely mimics the human prostate cancer progression.

Recent genetic mouse models and studies with cancer patients have firmly
demonstrated the critical roles of Hippo pathway in cancer development and
progression.

For

example,

Mst1

and

Mst2

suppress

development

of

hepatocellular carcinoma (HCC) in mice (18-20). WW45 heterozygous mice and
mice with a conditional deletion of WW45 in the liver develop osteosarcoma and
hepatoma (21). Although mutations are rare in Hippo pathway, mutation or
deletion of Lats2 is significant in malignant mesothelioma (22).

As the main downstream effectors of the Hippo pathway, YAP and TAZ do not
have any DNA binding domain thus they function as the transcriptional coactivators, promoting the downstream gene expression through binding with
multiple transcription factors. Among these transcription factors, the TEAD/TEF
family, which represent homologs of the Drosophila Sd protein, are the prime
mediators of YAP/TAZ function in Hippo Signaling. The YAP/TAZ-TEAD
transcription factor complex represents a common target of oncogenic
transformation. The oncoprotein YAP has been implicated in promoting several
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types of

tumor formation,

such

as liver and

skin

tumorigensis and

rhabdomyosarcoma (23-27). Specifically, the Tet-on inducible YAP transgenic
mice developed numerous discrete nodules in the liver after 8 weeks feeding with
water containing doxycycline, and further developed to widespread HCC after 3
months

(24). As

expected,

overexpression

or

hyperactivation

(nuclear

localization) of YAP is frequently detected in several human malignancies
including liver, ovarian, breast, lung and pancreatic cancer (24-26, 28-34). In
addition to the role of Hippo-YAP signaling in cancer development, recent studies
also implicate YAP involved in the metastatic progression of breast cancer and
melanoma (35). Although one study have shown that TAZ overexpression was
detected in 21% of primary breast cancers (36), a comprehensive study of TAZ
protein expression across multiple tumor types is unavailable at present.

Accumulated evidence has shown that the Hippo-YAP pathway activity is
regulated by many cues and factors, including cell adhesion, cell polarity, contact
inhibition/cell density, and cytoskeleton dynamics/mechanical forces (37, 38).
Recent studies have also demonstrated that YAP/TAZ activity can be regulated
independently of Hippo signaling and YAP/TAZ crosstalks with many other
canonical signaling pathways including Wnt/β-catenin (39-45), TGF-β/Smad (4648) and Ras-ERK (34, 49, 50)

in the regulation of cancer cell proliferation,

survival and tumorigenesis. Although YAP signaling is largely involved in
mediating these physiological processes, the biological significance of YAP in
prostate cancer has not been previously defined.
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Our study is the first study that explored the functional role of YAP in prostate
cancer cell motility, invasion and castration-resistant growth and determined the
clinical relevance of YAP in CRPC. Our data identify YAP as a critical regulator in
prostate cancer, especially for CRPC, providing an alternative mechanism
underlying the development of castration-resistance of prostate tumor cells.

2.2 Materials and Methods
Expression constructs
The pcDNA-YAP expression construct has been described (24). Point mutations
were generated by the QuikChange Site-Directed PCR mutagenesis kit
(Stratagene, La Jolla, CA, USA) and verified by sequencing. To make the
retroviral-mediated YAP expression construct, the above cDNA was cloned into
MaRXTMIV vector. The lentiviral YAP shRNA constructs and packaging vectors
(psPAX2 and pMD2.G) were from Addgene (Cambridge, MA, USA).

Cell culture and transfection
HEK293T, HEK293GP, RWPE-1, LNCaP cell lines were purchased from
American Type Culture Collection (ATCC, Manassas, VA, USA). HEK293T and
HEK293GP cell lines were maintained in DMEM containing 10% FBS and Lglutamine plus 100 units/ml penicillin and 100 µg/ml streptomycin (Invitrogen) at
37 °C in a humidified atmosphere containing 5% CO2. The LNCap cell lines were
maintained in ATCC-formulated RPMI-1640 Medium containing 10% FBS at
37 °C in a humidified atmosphere containing 5% CO2. The cell lines were
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authenticated at ATCC and were used at low (<25) passages. The LNCaP-C4-2
and LNCaP-C81 sublines have been described (51-53). All the transient
overexpression transfections were performed using Attractene (Qiagen) following
the manufacturer’s instructions. Cells were harvested at 2 days post-transfection.
RNA interference was performed using HiPerFect (Qiagen). For DNA and siRNA
co-transfection, Attractene reagents were used. siRNA oligonucleotides were
purchased from Dharmacom and GenePharma. YAP siRNA was synthesized by
GenePharma

based

on

the

following

target

sequence

(YAP-1:

5’-

CAGGTGATACTATCAACCAAA-3’; YAP-2: 5’-GACCAATAGCTCAGATCCTTT
(selected by Invitrogen online software). R1881 was purchased from PerkinElmer
(Waltham, MA, USA) All other chemicals were either from Sigma or Thermo
Fisher.

Retrovirus packaging and infection
To generate wild type YAP and YAP mutant overexpression stable cell lines,
retrovirus

infection was performed by transfecting HEK293GP cells with empty

MXIV-neo vector or MXIV-neo wild type YAP or YAP mutant constructs, following
the company’s instructions (Oligoengine). Each plasmid was co-transfected with
a construct expressing the VSV-G gene into the virus packaging cell line
HEK293GP to produce retrovirus expressing wild type YAP or YAP mutant. The
obtained retroviral supernatant was further filtered with 0.45µM filter and used to
infect the RWPE-1 and LNCaP cells with polybrene (Millipore) with the final
concentration of 10 µg/ml. At 24hours after infection, virus supernatant was
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replaced with fresh growth medium. The transduced cells were then selected at
800 µg/ml of neomycin (at 48hours post-infection) to establish stably expressing
YAP or YAP mutant cell lines. Western blot was used to test the expression level
of YAP.

Lentivirus packaging and infection
The LNCap-C4-2 cells were stably transfected with YAP shRNAs (purchased
from Addgene). Briefly, lentivirus infection was performed by transfecting
HEK293T cells with pLKO1-shYAP1 and pLKO1-shYAP2, following the
company’s instructions (Oligoengine). The plasmid (2.5 µg) was co-transfected
with the construct expressing psPAX2 (2.0µg) and pMD2.G (1.0µg) gene into the
virus packaging cell line HEK293T to produce lentivirus expressing YAP shRNA
with puromycin as the selectable marker, when HEK293T cells reached 50%
confluence. At 16hours after transfection, the medium was replaced and HEPES
(10 mM) and Sodium Butyrate (10 mM) were added to increase the half-life and
production of the virus. At 48 hours after transfection, the obtained lentiviral
supernatant was collected and further filtered with a 0.45 µM filter and used to
infect the LNCaP-C4-2 cells with polybrene (Millipore, Billerica, MA, USA) in the
presence of 10 μg/ml of polybrene. At 24hours after infection, the virus
supernatant was replaced with fresh growth medium. The transduced cells were
then selected with puromycin (2μg/ml) to establish cell lines in which YAP
expression was stably knocked down. Western blot was used to test the
expression level of YAP.
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Quantitative real time-PCR
Total RNA isolation, RNA reverse transcription and quantitative real time-PCR
were done as described previously (54). Other primer sequences are as follows:
TEAD1: cttgaatgtgcaatgaagcg (forward, F), cgaagtttgcctcggactc (reverse, R);
TEAD2:

ctcactccgtagaagccacc

gcaccttcttccgagctaga

(F),

(F),

tgccttcttcctggtcaagt

tacggccgaaatgagttgat

(R);

TEAD3:

(R);

TEAD4:

gctccactcgttggaggtaa (F), cttagcgcacccatccc (R);

YAP: acgttcatctgggacagcat

(F),

attcatcgccttcctagggt

(F),

ttggcaggctgatttctagg

(F),

actcctgagagaggacgcac

(F),

gtgtagcaccagatccatcg

(F),

gttgggagatggcaaagaca

ggctgggagatgaccttcac

(R);

(R);

ggtgcaaacatgtaacttttgg

CTGF:

(R);

cagggcagactggtagcaa

(R);

TAZ:

ITGB2:
ANKRD1:

cggtgagactgaaccgctat (R); Cyr61: cccgttttggtagattctgg (F), gctggaatgcaacttcgg
(R);

SOX4:

aatgtatgtttccccctccc

(F),

tcgctgtcgggtctctagtt

(R);

Survivin:

cgaggctggcttcatccact (F), acggcgcactttcttcgca (R); PSA: atatcgtagagcgggtgtgg
(F),

tcctcacagctgcccact

(R);

NKX3.1:

cagataagaccccaagtgcc

(F),

cagagccagagccagagg

(R);

KLK2:

tgtcttcaggctcaaacagg

(F),

gtacagtcatggatgggcac

(R);

PGC-1:

ctgctagcaagtttgcctca

(F),

agtggtgcagtgaccaatca (R).

Cell fractionation assay
Cell fractionation assays were done by NE-PER Nuclear and Cytoplasmic
Extraction

Reagents

following

the

Scientific/Pierce, Rockford, IL, USA).

manufacturer’s

instructions

(Thermo
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Antibodies and Western blot analysis
The YAP antibodies from Cell Signaling Technology (#4912, Danvers, MA, USA)
and Abcam (52771, Cambridge, MA, USA) were used for Western blotting
throughout the study. Anti-β-actin, anti-androgen receptor, anti-ERK1/2, anti-Akt,
anti-GSK3β, anti-β-catenin, anti-RSK1 and anti-RSK2 antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Mst1, anti-Mst2, antiLats1 and anti-Lats2 antibodies were from Bethyl Laboratory (Montgomery, TX,
USA). Anti-phospho-YAP S127, anti-phospho-Akt T308, anti-phospho-Akt S473,
anti-phospho-GSK3β S9, anti-phospho-ERK1/2, anti-phospho-Mst2 T180, anti-Ecadherin, anti-vimentin and anti-PARP antibodies were from Cell Signaling
Technology. Mouse monoclonal antibody against N-cadherin was provided by Dr.
Keith Johnson (University of Nebraska Medical Center) (55). Anti-phospho-RSK
S380 antibody was from Biolegend (San Diego, CA, USA). Anti-NF2 and anti-βtubulin antibodies were from Sigma (St. Louis, MO, USA). The cells were
harvested and cell lysate were prepared by 2XSDS lysis buffer. The proteins
were separated on SDS polyacrylamide gels and transferred onto PVDF
membranes (Millipore). HRP-conjugated anti-mouse or anti-rabbit IgG were from
Pierce. ECL and SuperSignal West Pico Chemiluminescent substrate kits (Pierce)
were used as HRP substrates.
Cell proliferation and anchorage-independent growth assays
For cell proliferation assays, 5,000 (LNCaP-C4-2) or 10,000 (LNCaP) cells were
seeded in wells of a 24-well plate in triplicate. Cells were counted by a
hemocytometer (Thermo, Waltham, MA, USA) and proliferation curves were
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made based on cell numbers of each well from three independent experiments.
Soft agar assays were conducted in 6-well plates. The base layer of each well
consisted of 1.5ml with final concentrations of 1 x media and 1% agarose. Plates
were chilled at room temperature until solid, at which point a 2 ml growth medium
with 0.5% agarose layer was poured, consisting of cells suspended (LNCaP-C42 cells: 5000 cells per well, LNCaP cells: 1X104 cells per well). Plates were again
chilled at room temperature until the growth layer congealed. A further 1 ml of 1x
culture media without agarose was added on top of the growth layer. The growth
medium was changed every week for 3-4 weeks, after which colonies were fixed
with 3.7% PFA and stained with 0.005% crystal violet for 1 minute followed by
PBS wash for 3 times of 5 minutes each. A picture was taken and total colonies
were counted. Data were obtained from three independent experiments.

Cell migration and invasion assays
In vitro analysis of invasion and migration was assessed using the BioCoat
invasion system (BD Biosciences) and Transwell system (Corning), respectively,
according to the manufacturer's instructions. The cells were trypsinized and
resuspended in the medium without serum and/or growth factor at the indicated
concentration (RWPE-1: 1.0X105/well, LNCaP 5.0X104/well, C4-2: 5.0X104/well
for migration assay; RWPE-1: 5.0X104/well, LNCaP 5.0X104/well, C4-2:
5.0X104/well for invasion assay). 600 µl of basal medium with 10%FBS was
added to the bottom of the migration assay chamber, and 750 µl for BioCoat
invasion chamber. The insert was carefully placed into each well to avoid leaving
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a bubble between insert and the medium in the bottom chamber. 100 µl or 500 µl
of the above mentioned cell suspension was added to the insert for migration and
invasion assay, respectively. After the incubation at 37°C for 18 to 24 hours, the
plate was removed from the incubator. The cells were fixed with 3.7% PFA and
the cells inside the inserts were removed with cotton swabs. Then, the invasive
and migratory cells were stained with ProLong® Gold Antifade Reagent with
DAPI. The relative invading and migrating rate were calculated by the number of
cells invading and migrating through the membrane, divided by the number of
cells that invaded and migrated in the control group.

Immunohistochemistry (IHC) staining
Tissue microarray slides (TMA) were obtained from the Prostate Cancer
Biorepository Network (PCBN, New York University site). The TMA consists of 7
naïve (hormone responsive) and 13 castration-resistant prostate cancer tumors
collected from 1983 to 2002 at New York University Langone Medical Center.
Slide deparaffinization, antigen retrieval, and blocking were performed as we
have described (24). The sections were then stained with anti-YAP antibody (Cell
Signaling #4912, at 1:100 dilutions) using a Histostain-Plus IHC kit following the
manufacturer’s instructions (Invitrogen, Grand Island, NY, USA). Cell nuclei were
stained with Hematoxylin. Ventana iScan HT (Roche) was used for slide
scanning with a 20X lens. The staining results were independently evaluated by
three researchers including two pathologists (S.M.L. and K.F.). Both the YAP
staining intensity (a scale of 0 to 3 was used: 0-negative, 1-weak, 2-moderate,
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and 3-strong) and nuclear localization (the percentage of tumor cell nuclei
stained, 0-no staining, 1-≤10%, 2-10-50%, and 3->50%) were scored (56).

Mouse xenograft Studies
For in vivo xenograft studies, LNCaP cells expressing vector or YAP in 50%
Cultrex (Trevigen, Gaithersburg, MD, USA) (2.0x106 each line/0.1 ml) were
subcutaneously injected into the left flank of 3-month-old castrated male SCID
mice (Charles River, Wilmington, MA, USA). Six or nine animals were used for
control (vector) and experimental (YAP) groups, respectively. Mice were
euthanized at 8 weeks post-injection and the tumors were excised and fixed for
subsequent histopathological examination and IHC analysis. The animals were
housed in pathogen-free facilities. All animal experiments were approved by the
University of Nebraska Medical Center Institutional Animal Care and Use
Committee.

Generation of prostate-specific Tet-on inducible YAPS127A transgenic mice
The Tet-on inducible system was used to generate prostate-specific inducible
YAP-S127A mice. We crossed the PB-rtTA mice to Tet-on YAP-S127A mice to
generate pups with both PB-rtTA and Tet-YAPS127A alleles. Since rtTA (reverse
tetracycline transactivator) is located downstream of the PB promoter, it is
specifically expressed in prostate tissue. As a result, in the presence of
doxycycline (fed with drinking water), rtTA binds to the tetracycline response
element and produces high level of YAP-S127A. Prostate of different ages of
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these male mice were dissected and histological analysis were performed to
check

the

formation

of

prostatic

intraepithelial

neoplasia

(PIN)

and

adenocarcinoma.

Generation of prostate-specific MST1/2 knockout mice
The Cre-LoxP system was used to generate mice with prostate-specific deletion
of Mst1/2. The Mst1

flox/flox

; Mst2

flox/flox

mice were mated with male PB-Cre mice.

PCR genotyping was used to determine the genotype of the offspring. Then the
male Mst1 flox/+; Mst2flox/+;Cre+ mice were mated with Mst1

flox/flox

; Mst2

flox/flox

mice

to generate the homozygous mice with prostate-specific deletion of Mst1/Mst2.
Prostate at different age of these male mice were dissected and histological
analysis were performed to check the formation of PIN and adenocarcinoma.

Mouse genomic DNA purification
3-week-old mice were weaned and 1/3-1/2 cm mice tails were cut for genomic
DNA purification. To each tail, 500ml of tail digestion buffer was added (which
has been supplemented with proteinase K at a final concentration of 0.5 mg/ml)
and placed at 55℃ for 16-24 hours. After vigorously shaking tubes for about 15
seconds, tubes were centrifuged at top speed for 15 minutes. Then the
supernatant was transferred to new micro-tubes containing 500ul isopropanol.
After 5 minutes incubation at room temperature, tubes were centrifuged at top
speed for 4 minutes. The DNA pallets were washed twice by adding 100ul 70%
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ethanol. Then add 200ul ddH2O and incubate for 1 hour at 55℃ to dissolve the
DNA. Then DNA was ready to use for PCR genotyping.

Genotyping
The PCR genotyping was performed using Promega GoTaq Flexi DNA
polymerase kit. All PCR reactions were set in the following 20ul system: DNA 2ul,
5 X Promega buffer 4ul, 25mM Mg2+ 1.6ul, 2.5mM dNTP 2ul, 10uM mixed primer
4ul, Promega enzyme 0.2ul, ddH2O 6.2ul.

Tissue processing
Mouse tissue was fixed in 3.7% PFA for 16h and then transferred to 70% ethanol.
Tissue embedding and slides preparation were performed by Tissue Science
Facility in UNMC.

Statistical analysis
Data were analyzed using a two-tailed, unpaired Student’s t-test. The Wilcoxon
rank sum test was used to compare the IHC staining data between groups. A P
value of <0.05 was considered as indicating statistical significance.
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2.3 Results
The Hippo Pathway Effector, YAP, Regulates Motility, Invasion and
Castration-Resistant Growth of Prostate Cancer Cells.
2.3.1 Upregulation and activation of YAP in prostate castration-resistant
tumors
To explore the functional significance of hippo pathway in prostate cancer, we
collected both clinical prostate normal and cancer tissues, and our data showed
that YAP was highly expressed in nearly all of the tumor samples examined
whereas relatively lower level in normal tissues (Fig. 2.1A). Interestingly, the
upstream tumor suppressor Mst1 expression was detected in only one of nine
tumor samples but three of the four normal samples (Fig. 2.1A). This suggests
that hippo pathway is dysregulated in human prostate cancer. We further mined
YAP expression data from large scale studies of prostate cancer. These data
confirmed that YAP mRNA was significantly high in CRPC or metastatic prostate
tumors compared to primary tumors (Fig. 2.1B,C).

YAP is overexpressed and/or hyperactivated (as shown by nuclear localization)
in prostate primary tumor samples (24, 32). However, it is not known to what
extent YAP activity/expression correlates with prostate castration resistance. To
determine the functional relevance of YAP in CRPC in the clinical setting, we
obtained tissue microarrays containing naïve (hormonal responsive) and
castration-resistant prostate tumors and performed immunohistochemical (IHC)
staining. Immunostaining demonstrated that overall YAP expression was
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relatively weak in naïve prostate tumors (Fig. 2.2A-A’’, n=7) and no single case
was scored moderate or strong for YAP staining (see ‘Materials and Methods’).
Importantly, we observed dramatic upregulation of YAP in most hormonal
therapy resistant tumor samples (Fig. 2.2B-E, n=13). Nine of the resistant tumors
showed moderate-strong staining and 4 of them had weak staining (compared
with all of the naive tumors showing weak to no staining) (p=0.003, resistant
versus naive). Furthermore, strong nucleus-localized (hyperactive) YAP staining
was detected in 5 of the resistant tumors (Fig. 2.2B-B’’, D-D’’ and F) (p=0.001,
resistant versus naive). These data indicates that YAP may function as a critical
regulator in the castration-resistant growth of prostate cancer.
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Figure 2.1 Upregulation of YAP in prostate tumors.
A. YAP and Mst1 protein levels in prostate normal and tumor samples.
B, Relative YAP mRNA levels in localized (primary) tumors and CRPC (resistant).
Data were mined from Grasso et al., 2012. N=60 (primary) and 36 (resistant). ***:
p<0.001 (t-test).
C, Relative YAP mRNA levels in primary and metastatic (Met) tumors (most
metastases are castration resistant). Data were retrieved from Gene Expression
Ominibus/GDS2545. N=65 (primary) and 25 (Met). ***: p<0.001 (t-test).
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Figure 2.2 Upregulation and activation of YAP in castration-resistant
prostate tumors.
A-A’’, Representative photos of immunostaining for YAP in naïve (hormonal
responsive) prostate tumors.
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B-B’’, C-C’’, and D-D’’ Representative photos of YAP IHC staining in hormonal
therapy-resistant prostate tumors.
E, Quantification of YAP IHC staining intensity in naive and castration-resistant
prostate tumors. Four resistant cases (3254108156, 8322079241, 8842201759,
6756440716) were scored low, five resistant cases (4024863604, 5962887148,
3698735602, 9182583214, 2667199309) were scored moderate and four
resistant cases (8063595154, 4976472144, 4729101711, 7346843168) were
scored high for YAP staining. All naïve tumors samples have no to low YAP
staining (4481786650, 2667199309, 8743000808, 4599423355, 8365207463,
8315345132, 2667199309).
F, Quantification of YAP nuclear localization based on IHC staining in naive and
castration-resistant prostate

tumors. Four resistant

cases (3254108156,

8322079241, 7346843168, 6756440716) were scored low, four resistant cases
(8842201759, 4024863604, 4729101711, 2667199309) were scored moderate
and five resistant cases (5962887148, 3698735602, 8063595154, 9182583214,
4976472144) were scored high for YAP nuclear staining. All naïve tumors
samples have no to low nuclear YAP staining. ***: p<0.001; **: p<0.01.
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2.3.2 YAP transforms prostate epithelial cells and promotes cell motility
and invasiveness
Previous studies showed that YAP overexpression induced transformation of
immortalized pancreatic and mammary epithelial cells (24, 26, 32). To investigate
the biological significance of YAP overexpession/hyperactivation in prostate
cancer, we first tested the role of YAP in RWPE-1 cells (immortalized prostate
epithelial cells). As shown in Figure 3, ectopic expression of YAP stimulated cell
proliferation and induced cellular transformation in RWPE-1 cells (Fig. 2.3A-D).
As expected, the expression of the constitutively active YAP-S127A (S127 is the
main Hippo-mediated phosphorylation site of YAP) mutant enhanced RWPE-1
cell proliferation and transformation to a greater extent than wild type YAP (Fig.
2.3B-D). YAP expression causes epithelial-mesenchymal transition (EMT) in
mammary epithelial cells (MCF10A) (26, 32). Surprisingly, YAP transformed
prostate cells without inducing an EMT as the levels of E-cadherin (epithelial
marker) and vimentin (mesenchymal marker) remained unchanged in the
presence of YAP activation (Fig. 2.4D). Consistent with this observation, YAP
was not sufficient to induce a full EMT in a non-transformed mammary epithelial
cell line (NMuMG) (35).

Over 90% of cancer deaths are due to metastasis rather than to primary tumors
(57, 58). Migration and invasion are essential steps for primary tumor cells to
metastasize and grow (58-60). We therefore examined the role of YAP in
prostate cell motility. Interestingly, overexpression of YAP or YAP-S127A also
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significantly promoted cell migration (Fig. 2.4A) and invasion (Fig. 2.4B, C) in
immortalized prostate epithelial cells. Next, we further explored whether
enhanced expression of YAP stimulates migration and invasion in prostate
cancer (LNCaP) cells. Similarly, YAP or YAP-S127A overexpression resulted in a
significant increase in number of LNCaP cells that invaded through Matrigel and
migrated through filters compared to vector control cells, respectively (Fig. 2.5AD). These data indicate that YAP activation is a positive regulator for prostate cell
oncogenic activity.
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Figure 2.3 YAP promotes cell proliferation and cellular transformation of
RWPE-1 cells.
A, Establishment of RWPE-1 cell lines stably expressing YAP.
B, Expression of YAP/YAP-S127A stimulates proliferation in RWPE-1 cells.
C, D, Anchorage-independent growth (colony formation assay) in soft agar.
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Figure 2.4 YAP promotes migration and invasion in RWPE-1 cells.
A-C, Cell migration (A) and invasion (B) assays with RWPE-1 cells expressing
vector, YAP or YAP-S127A constructs. Migrating and invading cells were stained
with DAPI and representative fields are shown (C). Quantitative data are
expressed as the mean ± s.e.m of three independent experiments. ***: p<0.001,
**: p<0.01, *: p<0.05 (t-test).
D, Westen blotting analysis with the indicated antibodies in YAP-expressing
RWPE-1 cells. ND: not detectable.
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Figure 2.5 YAP promotes migration and invasion in LNCaP cells.
A, Establishment of LNCaP cells expressing vector, YAP or YAP-S127A.
B-D, Cell invasion (B,C) and migration (B,D) assays with LNCaP cell lines
established in (A).
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2.3.3 YAP promotes castration-resistant growth of LNCaP cells
Most prostate cancer patients with metastatic disease progress to CRPC. We
next assessed whether YAP expression is sufficient to induce castration-resistant
growth in LNCaP cells, which grow completely in an androgen-sensitive/dependent manner. YAP overexpression stimulated proliferation of LNCaP cells
(Fig. 2.6A, B). Interestingly, the most significant change in these cells upon YAP
expression was the ability to proliferate normally under androgen-deprivation
conditions (using charcoal-stripped serum [CSS] to deplete the media of
androgens), in contrast, the control parental cells stopped dividing without
androgen (Fig. 2.6A, B). These data indicate that enhanced expression of YAP
was sufficient to convert LNCaP cells from androgen-sensitive to castrationresistant.

YAP was able to induce Akt and ERK activation in a cellular context-dependent
manner (49, 50). Interestingly, we also detected moderate but reproducible
increased phosphorylation of Akt on T308 (but not S473) upon YAP expression
(Fig. 2.6C). Both Akt and ERK were strongly activated upon androgen depletion
(Fig. 2.6C), suggesting that multiple cellular pathways are involved in prostate
cancer cell survival upon androgen deprivation.

TEAD1-4 (TEA domain containing protein) are the major transcriptional factors of
the Hippo pathway. Most of the known YAP/TEADs targets including ANKRD1
(ankyrin repeat domain 1), SOX4 (SRY(sex determining region Y)-box 4), CTGF
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(connective tissue growth factor) and Cyr61 (cysteine-rich angiogenic inducer 61)
were induced by YAP expression in LNCaP cells (Fig. 2.7A), indicating that YAP
signaling is on in LNCaP-YAP cells. Survivin and ITGB2 (integrin beta 2) were
not induced by YAP-overexpressing LNCaP cells (data not shown).

We further explored whether YAP could regulate androgen signaling activity.
Indeed, the AR (androgen receptor) targets PSA (prostate specific antigen),
NKX3.1 (NK3 homeobox 1), PGC-1(Peroxisome proliferator-activated receptor
gamma coactivator 1-alpha) and KLK2 (Kallikrein-2) were all greatly induced by
YAP overexpression (Fig. 2.7B), suggesting that YAP promotes AR activation.
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Figure 2.6 YAP promotes androgen-insensitive growth and Akt activation in
LNCaP cells.
A, Representative photos of LNCaP cells expressing vector or YAP that have
been cultured under normal (FBS) or androgen deprivation (CSS) media for 3
(FBS) or 5 (CSS) days. FBS: fetal bovine serum; CSS: charcoal-stripped serum.
B, Cell proliferation curve for various LNCaP cells.
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C, LNCaP cells expressing vector or YAP were cultured under normal (FBS) or
androgen deprivation (CSS) media for 3 days. The total lysates were probed with
the indicated antibodies.
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Figure 2.7 YAP induces its targets and AR activation in LNCaP cells.
A, Relative mRNA levels of known targets of YAP (by quantitative RT-PCR) in
LNCaP cells expressing vector or YAP.
B, Relative mRNA levels of known targets of androgen receptor (by quantitative
RT-PCR) in LNCaP cells expressing vector or YAP. Quantitative data are
expressed as the mean ± s.e.m of three independent experiments. ***: p<0.001,
**: p<0.01 (t-test).
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2.3.4 Upregulation of YAP in castration-resistant prostate cancer cells
We further assessed the extent to which YAP expression/activity is altered during
androgen-sensitive to castration-resistant progression. For this purpose, we took
advantage of a well-established prostate cancer cell model system. LNCaP cells
grow slowly and completely rely on androgen, whereas LNCaP-C81 and LNCaPC4-2 sub-lines (both of which are castration-resistant) grow aggressively even
under androgen-deprivation conditions. These cancer cell models closely
represent the transition of the initial androgen-sensitive disease to castrationresistant state (61, 62). Interestingly, we found that, compared to LNCaP cells,
YAP expression levels were dramatically upregulated in both LNCaP-C4-2 and
LNCaP-C81 castration-resistant cells (Fig. 2.8A). Phosphorylation of YAP on
S127 (the major phosphorylation site for the Hippo pathway) was proportionally
increased. Cell fractionation assays confirmed that the cytoplasmic-nuclear
localization of YAP was not significantly altered (Fig. 2.8B). In line with this
observation, no change was detected in the expression and activity of upstream
Hippo core components (Fig. 2.8A and data not shown). Consistent with previous
studies (63), AR levels were increased in LNCaP-C4-2 and LNCaP-C81 cells
compared to parental LNCaP cells (Fig. 2.8A). Finally, qRT-PCR showed that
YAP but not its paralog TAZ mRNA levels were significantly elevated in LNCaPC4-2 and LNCaP-C81 cells, indicating that transcriptional regulation was involved
in YAP upregulation (Fig. 2.8C and data not shown). Consistently, YAP targets
were induced in LNCaP-C4-2 cells (Fig. 2.8D). TEAD4 but not TEAD1-3 mRNA
was upregulated in LNCaP-C4-2 cells (Fig. 2.8E). YAP protein stability was
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similar in both LNCaP and LNCaP-C4-2 cells (data not shown). Together, these
results suggest that YAP was transcriptionally upregulated during the transition of
LNCaP cells to castration-resistant growth.
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Figure 2.8 YAP is upregulated in castration-resistant prostate cancer cells.
A, LNCaP (androgen-sensitive) and LNCaP-C81/LNCaP-C4-2 (castrationresistant) cell lysates were probed with the indicated antibodies. SE: short
exposure; LE: long exposure (A,B).
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B, Cell fractionation assay in LNCaP and C4-2 cells. The cells were harvested at
70-80 percent confluence. β-tubulin and PARP serve as cytoplasmic and nuclear
markers, respectively. C: cytoplasmic; N: nuclear.
C,D, Quantitative RT-PCR of YAP and its known targets in LNCaP and
castration-resistant sublines.
E, Quantitative RT-PCR of TEAD1-4 in LNCaP and castration-resistant sublines.
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2.3.5 YAP promotes castration-resistant growth in vivo
We next evaluated the influence of YAP on castration resistance in animals.
LNCaP-vector

control

and

–YAP-expressing

inoculated into castrated male mice (SCID).

cells

were

subcutaneously

As expected, most of the mice

(except one) injected with LNCaP-vector cells did not form palpable tumors (n=6).
However, about 67% (6/9) mice injected with LNCaP-YAP cells grew large
tumors at the end point of the experiment (Fig. 2.9A,B). The tumors on the mice
harboring YAP-expressing LNCaP cells were visible at one month post-injection
(data not shown). Histopathological examination revealed extensive tumor
necrosis and hemorrhage (Fig. 2.9C, H&E staining), which is an indicator of
aggressiveness. Most of these tumor cells express AR and YAP (Fig. 2.9C).
These data strongly suggest that YAP confers castration-resistant growth of
prostate cancer cells in vitro and in vivo.
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Figure 2.9 YAP confers castration resistance in vivo.
A, Castrated male SCID mice were implanted LNCaP-vector (top 6 mice) or
LNCaP-YAP-expressing (bottom row) cells and photographed at 8 weeks post
injection. T marks the tumor-harboring mice.
B, Tumor incidence of mice in A.
C, Hematoxylin and Eosin (H&E) and IHC staining of androgen receptor (AR)
and YAP. T: tumor area; N: necrotic area.
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2.3.6 YAP knockdown impairs migration and invasion in castrationresistant prostate cancer cells
To explore the biological significance of YAP upregulation in castration-resistant
prostate cancer cells, we reduced YAP expression by shRNA (constitutive) or
siRNA (transient) in LNCaP-C4-2 cells (Fig. 2.10A,B). Using Transwell and
Matrigel assays, we demonstrated that YAP knockdown greatly impaired
migration and invasion in LNCaP-C4-2 prostate cancer cells (Fig. 2.10C-J).
These data, together with gain-of-function of YAP (Figs. 2.3-7), suggest that YAP
plays an important role in motility and invasion in prostate cancer cells.
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Figure 2.10 YAP knockdown in LNCaP-C4-2 cells impairs cell migration and
invasion.
A, Establishment of cells stably expressing shRNA vector, and shRNAs against
YAP (shYAP#1 and shYAP#2) in LNCaP-C4-2 cells.
B, LNCaP-C4-2 cells were transiently transfected with control siRNA or siRNA
targeting YAP and YAP expression were analyzed by Western blotting.
C-F, Cell migration and invasion assays with LNCaP-C4-2 cells established in A.
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G-J, Cell migration and invasion assays with LNCaP-C4-2 cells transfected with
siRNA in B.

Cell migration assays with Transwell and invasion assays with

Matrigel were performed as we previously described(64). Migrating and invading
cells were stained with DAPI, and representative fields are shown. Data are
expressed as the mean ± s.e.m. of three independent experiments. ***: p<0.001,
**: p<0.01, *: p<0.05 (t-test).
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2.3.7 YAP is essential for castration-resistant growth of prostate cancer
cells
The upregulation of YAP in castration-resistant cell lines led us to further
determine whether YAP is required for growth without androgens in these cells.
Under normal growth conditions, LNCaP-C4-2 cells with YAP knockdown
showed only moderately slower proliferation than control LNCaP-C4-2 cells with
YAP expression (Fig. 2.11A, top panels, B). However, while LNCaP-C4-2 cells
were still able to proliferate (albeit at a slow rate) in the absence of androgens
(CSS media), YAP knockdown cells failed to divide under androgen deprivation
conditions (Fig. 2.11A,B). Consistent with this observation, LNCaP-C4-2 cells
with reduced YAP form colonies well in soft agar with complete serum (Fig.
2.11C,D); however, these cells failed to grow under CSS conditions (Fig.
2.11E,F). Again, LNCaP-C4-2 control cells, but not LNCaP-C-2 cells lacking YAP,
formed colonies even when androgens were removed (Fig. 2.11E,F). In total,
these studies implicate that YAP is essential for castration-resistant growth of
prostate cancer cells.

Consistent with our observations that YAP activated AR targets (Fig. 2.7B), YAP
knockdown reduced basal levels of PSA and NKX3.1 mRNA and partially
blocked the AR targets induced by R1881 (Fig. 2.12), further suggesting that
YAP regulates AR signaling activity.
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Figure 2.11 YAP is required for castration-resistant growth of LNCaP-C4-2
cells.
A, Representative photos of LNCaP-C4-2 cells expressing control shRNA or YAP
shRNA that have been cultured under normal (FBS) or androgen deprivation
(CSS) medium for 5 days. FBS: fetal bovine serum; CSS: charcoal stripped
serum.
B, Cell proliferation curve of various LNCaP-C4-2 cells.
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C-F, Anchorage-independent growth assay of LNCaP-C4-2 cells in soft agar
under normal (FBS) or androgen deprivation (CSS) conditions.
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Figure 2.12 YAP partially blocks the AR targets induced by androgen
analog.
Quantitative RT-PCR of YAP, PSA and NKx3.1 in LNCaP-C4-2 cells. Control and
YAP knockdown cells lines were cultured in serum-free medium for 24 h and
treated with or without R1881 (1 nM) for an additional 24 h. Data were derived
from three independent experiments and expressed as mean ± s.e.m. *: p<0.05;
**: p<0.01; ***: p<0.001 (t-test) when compared to control.
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2.3.8 YAP is required for ERK-RSK signaling activation upon androgen
depletion in LNCaP-C4-2 cells
We next explored the downstream signaling of YAP in castration-resistant growth
of prostate cancer cells. The PTEN/Akt axis and MEK-ERK signaling are critical
regulators in prostate tumor survival and progression (13, 65). Both Akt and
MEK-ERK pathways have been recently linked with YAP activity (34, 49, 50, 66).
Interestingly, we found that both Akt and ERK-RSK signaling pathways were
strongly activated upon androgen depletion (Fig. 2.13A,B), suggesting that
LNCaP-C4-2 cells proliferated without androgen, at least in part, by activating
these survival pathways. Importantly, ERK1/2 and downstream RSK1/2
activation (revealed by phosphorylation) was largely blocked in YAP knockdown
cells when androgens were removed (Fig. 2.13B). However, Akt activity was only
moderately reduced when YAP was knocked down (Fig. 2.13A). Together, these
data suggest that YAP is required for ERK-RSK activation in LNCaP-C4-2 cells
under androgen depletion conditions.

To determine the functional role of ERK activation upon androgen depletion, we
inhibited MEK-ERK signaling with the inhibitor U0126 and analyzed migratory
and invasive activity in LNCaP-C4-2 cells. ERK inhibition partially suppressed
migration under normal conditions and to a greater extent in media without
androgens (Fig. 2.14A,B). Interestingly, treatment with U0126 had no effect on
invasion under complete media, however, U0126 greatly impaired the invasive
ability of LNCaP-C4-2 cells under androgen-deprivation conditions (Fig. 2.14C,D).
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As expected, knockdown of YAP significantly reduced migration and invasion in
LNCaP-C4-2 cells (Fig. 2.14A-D). Taken together, our data indicate that ERK
activation (probably downstream YAP) is essential for LNCaP-C4-2 cells to
promote survival and migration/invasion under androgen depletion conditions.
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Figure 2.13 YAP is required for ERK-RSK activation upon androgen
depletion in LNCaP-C4-2 cells.
A,B, Cells were harvested at day 3 under normal (FBS) or androgen-depleted
(CSS) conditions and the total lysates were probed with the indicated antibodies.
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Figure 2.14 MEK-ERK inhibitor largely reduces migration and invasion
ability of LNCaP-C4-2 cells under androgen-deprivation condition.
A-D, Cell migration (A,B) and invasion (C,D) assays under normal (FBS) and
androgen-deprivation (CSS) conditions with or without MEK-ERK inhibitor U0126.
FBS: fetal bovine serum; CSS: charcoal stripped serum. ***: p<0.001(t-test); **:
p<0.01(t-test) when compared to control.
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Figure 2.15 A model for YAP signaling in castration-resistant prostate
cancer.
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2.3.9 Activated YAP promotes mouse prostate cell proliferation at early age
but is not sufficient to promote tumorigenesis in the mouse prostate
Having established the biological function of YAP in prostate tumorigenesis and
CRPC in cell culture and immunodeficient mouse, we further explored role of
Hippo-YAP signaling in prostate tumorigenesis by genetic transgenic mouse
models. First, we want to examine whether activated YAP is sufficient to induce
mouse prostate tumorigenesis or PIN. We crossed the PB-rtTA male mice to Teton YAP-S127A female mice to generate prostate-specific bi-transgenic mice (Fig.
2.16). Since rtTA is located downstream of the PB promoter, it is specifically
expressed in prostate tissue. As a result, in the presence of doxycycline
(administered through drinking water), rtTA binds to the tetracycline response
element and produces high levels of hyper-active YAP-S127A (Fig. 2.16).

After 10 days induction of doxycycline, activated YAP is more obviously detected
in the epithelial cells of mice prostate compared to the control mice, and ki67
staining showed increased proliferating cells (Fig. 2.17A). At 1 month, YAP is
more dramatically expressed in the transgenic mice prostate compared to the
control mice, and also more proliferating cells were detected (Fig. 2.17B),
indicating YAP stimulates prostate epithelial cell proliferation at the early state of
prostate development. However, after 14 months induction, we did not observe
any PIN lesion or adenocarcinoma formation in the mouse prostate although
YAP is still highly expressed (Fig. 2.18), suggesting that YAP is not sufficient to
promote prostate tumorigenesis in our transgenic mouse model.
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Figure 2.16 Generation of prostate-specific Tet-on inducible YAP-S127A
mice.
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Figure 2.17 Doxycycline induces YAP expression and epithelial cell
proliferation at early stage.
A, Adult single (left) or double (right) transgenic mice were fed with
Doxycycline water for 10 days, and prostate tissue were analyzed for
histology. YAP or ki67 IHC staining were performed.
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B, Adult single (left) or double (right) transgenic mice were fed with
Doxycycline water for 1 month, and prostate tissue were analyzed for
histology. YAP or ki67 IHC staining were performed.
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Figure 2.18 Activated YAP is not sufficient to promote tumorigenesis in the
mouse prostate.
Adult single (left) or double (right) transgenic mice were fed with Doxycycline
water for 14 months, and prostate tissue were analyzed for histology.
Hematoxylin & Eosin staining and YAP or ki67 IHC staining were performed.
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2.3.10 MST1/2 deletion is not sufficient to promote tumorigenesis in the
mouse prostate
We further explored whether deletion of tumor suppressor genes MST1/2 is able
to promote tumorigenesis in the mouse prostate. The Mst1flox/flox; Mst2flox/flox mice
were mated with male PB-Cre mice (Fig. 2.19). PCR-based genotyping was used
to determine the genotype of the offspring. Homozygous prostate-specific
deletion of Mst1/Mst2 were generated by breeding male PB-Cre+; Mst1flox/flox;
Mst2flox/flox to Mst1flox/flox; Mst2flox/flox mice. Littermates without PB-Cre were used
as controls.

As shown in (Fig. 2.20A), 45 days deletion of MST1/2 in prostate increased cell
proliferation indicated by ki67 staining. After 1 year deletion of MST1/2, still no
PIN or adenocarcinoma observed in the mouse prostate (Fig. 2.20B). Our results
suggest that specific deletion of MST1/2 in the prostate promotes cell
proliferation at early age but is not sufficient to induce prostate tumorigenesis.
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Figure 2.19 Generation of prostate-specific MST1/2 deletion.
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Figure 2.20 MST1/2 specific deletion is not sufficient to promote
tumorigenesis in the mouse prostate.
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A, Adult control (left) or prostate specific MST1/2 deletion (right) mice with
conditional MST1/2 knockout for 45 days, and prostate tissue were analyzed
for histology. MST1/2 or ki67 IHC staining were performed.
B, Adult controls (left) or prostate specific MST1/2 deletion (right) mice with
conditional MST1/2 knockout for 1 year, and prostate tissue were analyzed
for histology. Hematoxylin & Eosin staining and MST1/2 or ki67 IHC staining
were performed.
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DISCUSSION
Androgen deprivation therapy initially decreases the volume of both primary and
metastatic lesions, however most men experience eventual relapse. Recurring
prostate cancer is typically ‘castration-resistant’ since removal of testicular
androgen by chemical or surgical castration does not affect tumor growth or
metastasis. Ultimately, the vast majority of CRPC is lethal. Thus, there is an
urgent need to identify drug targets, and develop new therapeutic strategies to
treat CRPC. Although the underlying mechanisms of castration resistance are
not fully understood, both androgen receptor-dependent and –independent
signaling pathways are known to be involved (67). Androgen receptor
overexpression, activation and androgen secretion are the major contributors to
androgen receptor-dependent CRPC (67-69). For example, androgen receptor
selectively upregulates M-phase cell-cycle genes to promote CRPC (70).
Interestingly, a recent study found that a gain-of-function mutation in
dihydrotestosterone (the most potent androgen) synthesis partially accounts for
castration resistance (71). However, some other studies have challenged the
androgen receptor-dependent mechanism, as castration induces many kinases
activation (72) and increases the expression of anti-apoptotic genes independent
of the androgen receptor (73). Furthermore, prostate cancer stem cells have
been proposed to be the origin of prostate cancer progression and they may not
express androgen receptor (74). Our current study implicates YAP as a potent
regulator for CRPC in vitro and in vivo (Figs. 2.3-9) and in clinical samples (Figs.
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2.1,2), thus identifying YAP as a potential alternative regulator/pathway for the
acquisition of castration resistance of prostate tumor cells.

Hippo-YAP signaling is often deregulated in cancer and is a potential target for
cancer therapy (37, 75, 76). Among the components, the YAP/TEAD complex
represents the most attractive target for several reasons. First, TEAD
transcription factors are required for YAP’s oncogenic activity both in cell culture
and in vivo (77, 78). Second, TEAD is largely dispensable during normal tissue
growth in the mouse liver (78) and in Drosophila (64) (i.e., TEAD becomes critical
only when YAP is hyperactivated/overexpressed). Thus, there is a strong
rationale for developing YAP-TEAD complex-disrupting agents as anti-cancer
therapeutics against YAP-driven oncogenesis. Indeed, Liu-Chittenden et al.
screened a small molecule library (consisting of 3,300 FDA-approved drugs) for
agents that inhibit YAP/TEAD activity in a cell-based assay (78). Verteporfin was
identified as an compound effective at preventing hepatic tumorigenesis driven
by YAP overexpression (78) and the growth of xenograft tumors in
immunodeficient mice (56, 57). Thus, verteporfin is an effective pharmacologic
approach to inhibit YAP signaling, and these studies strongly support the
feasibility of targeting YAP in human cancer in which Hippo-YAP is deregulated.
Importantly, the current study showed that depletion of YAP could cause
castration-resistant prostate cancer cells to stop growing and become androgensensitive (Figs. 2.6,10,11,13). Therefore, inhibiting YAP (e.g. by verteporfin)
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combined with hormonal therapy is a potential novel therapeutic strategy for
prostate cancer patients with CRPC (Fig. 2.15).

Previous studies, including ours, demonstrated that YAP is overexpressed or
hyperactivated in prostate tumor samples (24, 32). Furthermore, Lats2
expression is significantly lower in metastatic prostate tissues when compared to
normal prostate samples (79). Interestingly, Lats2 and Mst1 have been shown to
be associated with androgen receptor and regulate its activity (80, 81). These
reports suggest that the Hippo-YAP pathway plays a role in the pathogenesis of
prostate cancer. This study adds further evidence showing that the Hippo effector
YAP regulates cell motility, invasion and castration-resistant growth of prostate
cancer cells. Together, these studies demonstrated the biological significance of
the Hippo-YAP signaling in prostate cancer. There are several questions that
need to be addressed. How is YAP upregulated in castration-resistant prostate
cancer cells? Our observations suggest that the upregulation of YAP is androgen
receptor-independent and methylation is dispensable for YAP transcription in
LNCaP and C4-2 cells (L.Z. and J.D., unpublished observations). Large scale
studies failed to identify YAP amplification and mutation in CRPC. Therefore,
future studies are needed to address the underlying mechanisms of YAP
upregulation in CRPC. Furthermore, how is Hippo-YAP deregulated and what are
the clinical outcomes? Answers and understanding from these questions may
provide additional insights into the pathogenesis of prostate cancer.
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Genetically engineered mouse alleles of the most Hippo components are
available and these animal models provided compelling evidence showing the
importance of Hippo-YAP signaling in human malignancies (18-20, 23-27, 82,
83). However, no single such model has been developed in the prostate. Our
transgenic mouse studies showed that activated YAP or specific deletion of
MST1/2 promotes mouse prostate cell proliferation at early age but is not
sufficient to promote tumorigenesis in the mouse prostate. It is possible that only
YAP activation or loss of MST1/2 is not sufficient to induce prostate
tumorigenesis, and combination of additional alleles is necessary to induce
prostate cancer. Since PTEN is an important tumor suppressor in prostate
cancer, and specific deletion of PTEN in prostate leads to metastatic prostate
cancer and castration resistance (84, 85), we are currently trying to combine the
PTEN alleles with the Hippo (loss-of-function)-YAP (gain-of-function) signaling. A
recent report showed that Mst1/2 deletion or YAP activation could downregulate
PTEN, suggesting a potential link between Hippo-YAP pathway and PTEN
signaling (66).
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